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Abstract
The citrus flavonoid nobiletin has lipid lowering and insulin sensitizing properties. In mice,
nobiletin supplementation prevents high fat diet-induced dyslipidemia and insulin resistance.
Interestingly, triglyceride mass remains elevated in the intestine of fasted high fat-fed mice,
but not in nobiletin-supplemented mice. In this thesis, the mechanisms underlying the
prevention of intestinal triglyceride retention by nobiletin were investigated. In male Ldlr-/mice, nobiletin corrected intestinal insulin signaling resulting in normalization of de novo
lipogenesis and decreased triglyceride for chylomicron synthesis and storage. In response to
an oral fat load, nobiletin increased chylomicron-triglyceride secretion into plasma and
enhanced plasma triglyceride clearance resulting in attenuated postprandial lipemia.
Nobiletin also normalized gut hormone signaling and pancreatic β-cell mass to prevent
hyperinsulinemia. Although nobiletin increased plasma GLP-2, GLP-2 antagonist
administration did not inhibit nobiletin-induced chylomicron secretion. Finally, nobiletin
protected high fat-fed female Ldlr-/- mice from dysregulated intestinal triglyceride
metabolism but not from atherogenic cholesterol metabolism. These studies provide evidence
for the therapeutic utility of nobiletin in improving intestinal insulin signalling and intestinal
lipid metabolism.
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Summary for Lay Audience
A natural compound isolated from tangerine peels called nobiletin has beneficial properties
including improving the action of insulin. Insulin is a hormone secreted from the pancreas
into the blood stream after a meal that helps cells of our body to use and store the energy
(glucose) from our diet. Overconsumption of high-calorie foods causes an over-secretion of
insulin and eventually, cells become resistant to insulin action. When we feed mice a high-fat
diet, they develop insulin resistance, obesity, high levels of blood fats (such as cholesterol)
and fat accumulates in fat cells as well as in other organs such as the liver. Previously, we
have reported that in mice, adding nobiletin to a high-fat diet corrects insulin resistance,
prevents obesity, lowers blood fats and prevents liver fat accumulation. Nobiletin works by
increasing the burning of fats in the liver. The small intestine, which is responsible for
absorbing and packaging dietary fat for delivery into the bloodstream, has been shown to
contribute to dangerous blood fat levels. We asked the question – Does nobiletin also
improve the way the small intestine handles fat? Intriguingly, when mice are fed a high-fat
diet, but not a low-fat diet, the small intestine accumulates fat, even in the fasted state. The
addition of nobiletin to the high-fat diet completely prevented this fasting fat accumulation.
In this thesis, we studied how nobiletin prevents fasting intestinal fat accumulation. In male
mice, nobiletin prevented insulin resistance in cells of the intestine resulting in the
normalization of the amount of fat stored. In response to a fat meal, nobiletin increased the
rate at which packaged fat exits the intestine and enters the blood stream. Once in the blood,
the rate at which this blood fat was cleared from the circulation was much faster compared to
mice fed the high fat diet alone. In the pancreas, nobiletin normalized insulin stimulation and
decreased insulin storage to prevent high-blood insulin. We also investigated the protective
effects of nobiletin, for the first time, in female mice. Nobiletin prevented obesity and fasting
fat accumulation in the intestine. While some blood fats were normalized with nobiletin
treatment, cholesterol levels were just as high as in the mice fed the high-fat diet alone. These
studies provide new evidence for the contribution of the intestine to high blood-fat levels,
iii

they highlight the potential of nobiletin as a treatment and they demonstrate the importance
of studying both sexes.
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Chapter 1

1

Introduction

Cardiovascular diseases (CVDs) are the leading causes of death in the world [1]. A major
contributor to CVDs in Western countries is atherosclerosis [1]. This progressive disease
is characterized by an accumulation of lipid-rich necrotic debris, smooth muscle cells,
and cholesterol-overflowing macrophages in large arteries [2]. These accumulations lead
to plaque formation, which grow into lesions in the blood vessel wall [2]. These lesions
can either grow large enough to block blood flow or rupture to form a devastating
thrombus, resulting in a heart attack or a stroke [2]. The development of effective
therapeutics depends on our understanding of the underlying mechanisms leading to
atherosclerosis.

1.1 Lipoproteins
The insolubility of lipids, such as cholesterol and triglycerides, requires their transport to
be associated with proteins in blood [3]. Lipoproteins are composed of a hydrophobic
core, which contains non-polar lipids such as cholesteryl ester and triglycerides [3]. This
core is surrounded by phospholipids, free cholesterol and apolipoproteins that together
form a hydrophilic monolayer [3]. The different sizes, lipid compositions and
apolipoprotein signatures of the lipoprotein distinguish plasma lipoproteins into seven
classifications (Table 1) [3]. Moreover, the apolipoprotein signatures are largely
responsible for the metabolic fate of these lipoproteins.
Chylomicrons produced by the intestine and are mainly composed of triglycerides on an
apolipoproteinB48 (apoB48) protein scaffold. They are the largest plasma lipoprotein and
are responsible for the transport of dietary fat to peripheral (non-liver) tissues [4, 5].
VLDL particles are liver-derived and are mainly composed of triglycerides on an
apoB100 protein scaffold [3]. While VLDL particles are smaller than chylomicron
particles, their size reflects the amount of endogenous triglyceride synthesized in the liver
[3]. Catabolism of VLDL particles results in cholesterol-enriched intermediate density
lipoprotein (IDL) [3]. Derived from VLDL and IDL particles are the low-density
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lipoproteins (LDL), the primary blood cholesterol carrier in humans [3]. Finally, HDL
particles are synthesized primarily in the circulation on a apoA-1 protein scaffold and are
responsible for reverse cholesterol transport from the periphery to the liver [3].
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Table 1.1 Classes of lipoproteins

Chylomicron

PL

VLDL

TG

FC

LDL

CE

HDL

Apopn

Diameter
(nm)

>75

30-80

18-25

5-12

Density
(g/mL)

<0.95

0.95-1.006

1.019-1.063

1.063-1.210

Source of
production

Intestine

Liver

VLDL/IDL
catabolism

Liver and
intestine
derived
apoA1

Associated
lipoproteins

AI, AII, AIV,
AV, B48, CI,
CII, CIII, E

AV, B100, CI,
CII, CIII, E

B100

AI, AII, AIV,
AV, CI, CII,
CIII, E, M

PL; phospholipid
TG; triglyceride
FG; free cholesterol
CE; cholesteryl ester
Apopn; apolipoprotein

Adapted from Doonan et al. (2019) Biochem Biophys Acta. 1863: 762-771
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1.2
1.2.1

Lipoprotein metabolism
Exogenous lipoprotein metabolism

Enterocytes, the absorptive cells in the gut, are dynamic responders to the ingestion of
food [6] and are responsible for absorbing and packaging lipids for distribution as
chylomicrons throughout the body. Greater than 95% of dietary fat is absorbed, while
approximately only 50% of dietary cholesterol is absorbed following the consumption of
a meal [3]. Once in the lumen of the small intestine, pancreatic lipase hydrolyzes dietary
triglycerides into free fatty acids and monoacylglycerols [7]. Hydrolyzed fats associate
with bile acids, cholesterol, phospholipid, plant sterols, and fat-soluble vitamins to form
mixed micelles, which facilitate both passive and active transport of FAs into the
enterocyte [3]. While the entire small intestine is biologically capable of absorbing
dietary fat, the jejunum performs the bulk of this process [5]. CD36 is a fatty acid
transporter highly expressed in jejunal villi responsible for some FA absorption, whereas
the remainder crosses the brush border membrane by passive diffusion [3]. Cholesterol
and plant sterol absorption, on the other hand, is facilitated by Niemann-Pick C1-like 1
protein (NPC1L1), whose activity is inhibited by ezetimibe as a cholesterol-lowering
therapy [3].
Upon entry into the enterocyte, cholesterol and plant sterols are subject to one of
two fates: transport back into the intestinal lumen by the ABCG5 and ABCG8
heterodimer sterol transporter, or conversion to sterol esters by acyl-CoA cholesterol acyl
transferase (ACAT) [3]. Approximately 95% of plant sterols and 50% of dietary
cholesterol are transported back into the lumen by ABCG5 and ABCG8 [3]. In parallel,
fatty acid binding proteins transport absorbed fatty acids to the endoplasmic reticulum
(ER) of the enterocyte [5]. Here, fatty acids are resynthesized into triglyceride while
cholesterol is converted to cholesteryl ester by ACAT. Acyl-CoA synthetase activates
fatty acids to fatty acyl-CoA [5, 7]. Fatty acyl-CoAs are primarily incorporated into
triglyceride molecules in the fed-state, where monoacylglycerol acyltransferase (MGAT)
catalyzes the addition of one FA-CoA to a monoacylglycerol [5]. Triglyceride formation
is completed by the actions of diacylglycerol transferase (DGAT), which catalyzes the
addition of FA to diacylglycerol. At this point, triglycerides and cholesterol esters are
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catalyzes the addition of one FA-CoA to a monoacylglycerol [5]. Triglyceride formation
is completed by the actions of diacylglycerol transferase (DGAT), which catalyzes the
addition of FA to diacylglycerol. At this point, triglycerides and cholesterol esters are
subjected to one of two fates: they are either loaded onto the newly synthesized apoB48
scaffold protein for chylomicron secretion into circulation or they enter cytoplasmic lipid
droplets (CLDs) for temporary storage within the enterocyte [4, 7, 8].

1.2.1.1

Apolipoprotein B-48 (apoB48)

Each chylomicron particle contains one apoB48 protein, which serves as a scaffold
protein essential for chylomicron synthesis and secretion [3-5]. Dietary fat stimulates the
production of apoB48 in intestinal enterocytes from the apoB primary sequence. During
translation, a large multiprotein complex including (apobec)-1 converts codon 2153
(CAA) to a premature stop codon (UAA) in apoB mRNA; this truncation event yields
48% of the mature apoB sequence [9]. As a result, the C-terminal portion of apob48 lacks
the LDL receptor-binding domain, thus preventing hepatic uptake and clearance of
chylomicrons [9]. Importantly, APOBEC-1 arises from the APOBEC1 gene, which is
highly expressed in the small intestine and is absent in the liver in humans [9]. Mice,
however, express Apobec-1 in both the liver and the intestine, allowing both apoB100
and apoB48 to be produced in the liver [5].

1.2.1.2

Chylomicron assembly and secretion

Microsomal triglyceride transfer protein (MTP) assists in apoB folding and catalyzes the
transfer of triglycerides, cholesteryl esters and phospholipids onto apoB48 as it is being
translated into the ER lumen [9]. The resulting primordial chylomicron particle
undergoes further lipidation and acquires ApoA-IV, forming a pre-chylomicron particle
[9]. Pre-chylomicron transport vesicles facilitate the export of pre-chylomicrons from the
ER to the Golgi [9]. This complex fuses with the cis-Golgi, where transported prechylomicron particles acquire Apo-AI and Apo-AII, forming mature chylomicron
particles. Vesicles then transport mature chylomicrons from the Golgi to the enterocyte's
basolateral surface for exocytosis into the lymph vasculature [4].
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Figure 1-1 Triglyceride processing in intestinal enterocytes.
Pancreatic lipases in the intestinal lumen hydrolyze dietary triglyceride (TG) into
monoacylglycerol (MG) and fatty acids (FA). CD36, fatty acid binding protein (FABP)
and fatty acid transporter protein facilitate FA absorption into the enterocyte. In the
enterocyte, FAs are re-esterified into TG in the endoplasmic reticulum (ER) first by mono
acylglycerol transferase (MGAT) and then by diacylglycerol acyltransferase (DGAT) 1
or 2. TG within the ER can either be stored in cytoplasmic lipid droplets (CLD) for
temporary storage, or it can be transferred to the Golgi where it is loaded onto apoB48
scaffold protein for chylomicron formation.
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Insulin Sensitive Intestine
Insulin

Intestinal
lumen
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mTOR
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p

gluconeogenesis
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TG
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FATP

FA-CoA
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ER

Adapted from Lee B et. al. J Lipid Res. 2010;51:1770-1780
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1.2.1.3

Chylomicron catabolism

Chylomicrons are secreted into the lymph, where they acquire apoC-II, C-III and E
mainly from HDL [9]. Chylomicrons enter the circulation at the left subclavian vein via
the thoracic duct [5], which is specifically designed for primary delivery of energy-rich
fatty acids to the energy-demanding heart. Lipoprotein lipase (LPL) is highly expressed
in heart, muscle and adipose tissue and is anchored to glycosylphosphatidylinositol
anchored high density lipoprotein binding protein 1 (GPI-HBP1) on the luminal surface
capillary endothelial cells [3, 9]. LPL hydrolyzes TG within the core of postprandial
chylomicrons and its activity is modulated by chylomicron-associated apoC-II
(activation) and apoC-III (inactivation) [9]. Most of the released fatty acids cross
endothelial cells and are transported by CD36 and FAPBs into peripheral tissues for
energy production or storage, while some bind to albumin for transport to other tissues
[3]. The resulting triglyceride-depleted and now cholesterol-enriched chylomicron
remnant acquires apo E from HDL in exchange for phospholipids, apoAs and apoCs. Apo
E facilitates chylomicron remnant binding to the LDL or LRP receptor on the hepatocyte
membrane for uptake into the liver [3]. Once peripheral tissues acquire triglycerides from
chylomicron particles, the resulting particle is now smaller, enriched in cholesteryl ester
and is called the chylomicron remnant [3].
Overall, chylomicron particles enable efficient delivery of dietary fatty acids to
the periphery for energy utilization and storage. Chylomicron remnant particles enable
the delivery of dietary cholesterol to the liver for VLDL and bile acid synthesis [3].
Under normal conditions, there is little difference between the number of apoB48containing particles secreted from the intestine in the fasting and postprandial states; their
size, rather, depends on the amount and type of fat absorbed [9].
Gender, genetics, age, body size, exercise, weight loss and metabolic syndrome (MetS)
influence postprandial lipid secretion [9]. Furthermore, fatty acid composition
significantly alters postprandial lipid secretion, where meals enriched in n-3
polyunsaturated fatty acids decrease postprandial triglyceride secretion compared to
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meals high in saturated and monounsaturated fatty acids [9]. There is epidemiological
evidence that both fasting and postprandial hypertriglyceridemia are important risk
factors for CVD.

1.2.1.4

Cytoplasmic lipid droplets (CLD)

As previously mentioned, triglycerides derived from dietary fatty acids that are not
assembled into the primordial chylomicron particle are temporarily stored into CLDs.
Budding of excess triglyceride molecules from the smooth endoplasmic reticulum is
currently the most supported proposed mechanism for CLD synthesis [5]. CLDs continue
to accumulate triglycerides and increase in size through triglyceride synthesis at the CLD
surface, phospholipid synthesis for monolayer expansion and by fusing with other CLDs
[5]. While generally much larger than chylomicrons, CLDs share some similar features
such a large triglyceride and cholesteryl ester cores surrounded by a monolayer of
phospholipids, free cholesterol and proteins, including perilipins [5].
Dietary fat consumption increases the number and size of CLDs in mice, where
the majority of CLDs are found in enterocytes of the proximal jejunum [5]. CLD
synthesis appears to attenuate FA toxicity and control chylomicron synthesis and
secretion rates in response to high-fat challenges [5]. The number and size of CLDs
decrease with fasting time, suggesting that CLD stored triglycerides are hydrolyzed at
later time points and released fatty acids are either re-synthesized into triglycerides for
chylomicron synthesis and secretion, directed toward fatty acid oxidation or are used for
other cellular purposes [5, 8]. Emerging studies underline the importance of intestinal
FA-oxidation activity in altering enterocyte triglyceride storage. In mice, chronic high-fat
feeding upregulates FA-oxidation and corresponding gene expression compared to lowfat fed mice. This upregulation in FA-oxidation may be important in providing additional
energy to enterocytes required for the increased dietary fat absorption or in limiting FA
availability to reduce postprandial lipemia [5]. Cytoplasmic lipolysis and/or lysosomal
lypolysis (lipophagy) have been proposed as mechanisms of CLD catabolism, although
the complete mechanism has not been fully elucidated. Important players in CLD
lipolysis that have been identified on these structures in enterocytes using proteomics
include adipocyte triglyceride lipase (ATGL). In particular, triglyceride storage in CLDs
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inversely correlates with enterocyte ATGL activity, which hydrolyzes triglyceride ester
bonds and directs the products towards oxidation [5]. Emerging studies have identified
CLDs as substrates for autophagy, where autophagosomes engulf CLDs and deliver them
to the lysosome; here, lysosomal acid lipase (LAL) hydrolyzes ester bonds. While a
relatively new area of research, diet, hormones, transcription factors and signaling
systems have all been identified as regulators of enterocyte CLD metabolism [5].

1.2.2

Endogenous lipoprotein metabolism

Hepatocytes are the workhorses of the hepatic lipid metabolism whereby they are
responsible for lipid uptake, esterification, oxidation, storage and secretion of VLDL
[10]. Sources of hepatic FAs include diet (15-30%), de novo lipogenesis (up to 30%) and
FAs released from adipose tissues during fasting [10]. VLDL synthesis begins with
apolipoprotein B-100 (apoB100) translocation across the endoplasmic reticulum (ER)
membrane [11]. MTP, like in the intestine, facilitates the partial lipidation of apoB with
triglyceride, cholesteryl ester and phospholipid during the translation of apoB
polypeptide, which also prevents its degradation [10, 11]. The resulting pre-VLDL
particle fuses with neutral lipid droplets in the ER lumen to continue lipidation [11].
Therefore the availability of triglycerides drives the rate of VLDL synthesis. Next, VLDL
particles are transported to the cis-Golgi by VLDL transport vesicles for glycosylation
and phosphorylation. VLDL-containing secretory vesicles fuse with the sinusoidal
membrane and are then secreted into the space of Disse, and into circulation where the
acquire apoCII, CIII and some apoE from HDL [11]. VLDL particles are transported in
the circulation and triglycerides are hydrolyzed by capillary endothelial cell-bound LPL
and therefore compete with chylomicrons for clearance [9]. VLDL hydrolysis results in
the formation of smaller, denser, cholesteryl ester-enriched intermediate density
lipoproteins (IDL) that acquire more apoE from HDL particles [12]. At the hepatocyte
cell surface, IDL particles are further depleted of triglyceride by hepatic lipase or LPL.
Approximately 50% of these modified IDL particles are cleared by the liver via binding
of apoE to LDL and LRP receptors, while the remaining ~50% becomes LDL, the
predominant cholesteryl ester carrier in the circulation [12]. Therefore VLDL metabolism
produces LDL particles.
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Since LDL particle production depends on IDL particle availability for
triglyceride depletion, LDL particle production is also under the regulation of LDLR
activity [3]. In other words, a decrease in LDLR activity will lead to an increase in LDL
particle production. Moreover, approximately 70% of LDL particles are cleared by liver
LDLR mediated endocytosis [3]. An increase in hepatic LDLR number will lead to an
increase in LDL particle clearance and therefore a decrease in plasma LDL.

1.2.2.1

The LDL receptor (LDLR)

The LDLR has a well-established role in clearing circulating lipoprotein particles [13].
The LDLR localizes to the cell surface and contains five functional domains: the ligand
binding domain, the epidermal growth factor (EGF) receptor homology domain, the Olinked glycosylation domain, the hydrophobic transmembrane domain and the
cytoplasmic domain [14]. The N-terminus is the ligand-binding domain, by virtue of its
negatively charged region, which interacts with the positive charges present on apoB and
apoE proteins thereby enabling the clearance of LDL, chylomicron remnants and IDL
particles [3,14]. The EGF domain contains a region for n-linked glycosylation, which is
required for secretion of LDLR, and the binding domain for proprotein convertase
subtilisin/kexin type 9 (PCSK9) [12]. The O-linked glycosylation domain is also
extracellular and is required for secretion [14]. The hydrophobic nature of the fourth
domain allows for receptor anchorage to the cell surface. The final domain of the LDLR
is the C-terminus cytoplasmic tail, which is required for anchorage and contains the
NPxY sequence; this sequence directs the LDLR to clathrin-coated pits for endocytosis in
response to the binding of LDLR associated protein 1 (LDLRAP1) [14]. Once
internalized into endosomes, the LDLR can dissociate from the lipoprotein and be
recycled to the cell surface; the endosome fuses with lysosomes resulting in lipoprotein
degradation and release of cholesterol to the ER membrane. Alternately, internalization
of LDLRs bound to PCSK9 are not recycled and are targeted for lysosomal degradation
[12].
Hepatocytes continuously sense the cholesterol availability within the cell,
primarily within the ER, and respond to maintain homeostasis. The expression of LDLR
at the cell surface is inversely related to the intracellular cholesterol content [13]. At the
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gene expression level, low cellular cholesterol triggers the translocation of transcription
factor SREBP from the endoplasmic reticulum to the Golgi. Activation of SREBP at the
Golgi allows for migration to the nucleus and subsequent initiation of the expression of
the LDLR as well as HMG-CoA reductase, the rate-limiting enzyme in cholesterol
synthesis [3]. High cellular cholesterol levels not only keep SREBP inactive in the
endoplasmic reticulum, but they also oxidize as they accumulate [3]. Oxidized sterols
also keep SREBP inactive, but they can activate LXR, a nuclear hormone receptor that
stimulates transcription of E3 ubiquitin ligase called inducible degrader of the lowdensity lipoprotein receptor (IDOL). As the name suggests, IDOL targets LDLR for
degradation [3]. Therefore, the cell can regulate its cholesterol content by controlling
endogenous synthesis and well as LDLR mediated lipoprotein cholesterol uptake from
the circulation.

1.2.3

Reverse cholesterol transport

To maintain cellular cholesterol homeostasis, HDL transports excess peripheral
cholesterol to the liver for excretion into bile and feces [15]. The intestine and the liver
synthesize and secrete apoA-I, the main structural protein for HDL formation [9].
Following secretion, apoA-I acquires cholesterol by interacting with the cholesterol
transporter ATP Binding Cassette AI (ABCA1) expressed by hepatocytes and enterocytes
[16]. The resulting pre-β HDL particles continue to acquire free cholesterol and
phospholipids from peripheral cells via ABCA1 as well as from the lipolysis of
chylomicrons and VLDL particles. The latter process partly contributes to the strong
inverse correlation between triglycerides and HDL-cholesterol [3, 16]. HDL-apoA-I
activates lecithin cholesteryl acyl transferase (LCAT), which catalyzes the
transesterification of fatty acids from phospholipids to the free cholesterol to form
cholesteryl ester. This newly formed cholesteryl ester is more hydrophobic and localizes
from the surface monolayer to the core of the growing HDL particle [3, 16, 17]. These
more mature HDL particles can acquire more cholesterol from peripheral cells via
ABCG1. In humans, CETP facilitates the transfer of cholesteryl ester from HDL to apoB
containing particles in exchange for triglyceride for further metabolism. Mice, however,
do not express CETP and therefore have relatively high HDL cholesterol levels and low
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LDL cholesterol levels [3]. The liver selectively takes up HDL cholesteryl ester via
scavenger receptor BI (SR-B1) and the resulting smaller apoA-I containing HDL particle
returns into the circulation [16]. The delivered cholesterol can either be converted to bile
acids or directly secreted in bile. The latter process is achieved by liver ABCG5 and
ABCG8, which are under the regulation of LXR [3].

1.3
1.3.1

Fatty acid and cholesterol metabolism
Fatty acid and triglyceride synthesis

De novo lipogenesis is the insulin-dependent synthesis of fatty acids from carbohydrates
[32]. Insulin-sensitive liver and adipose tissues perform de novo lipogenesis to provide
energy to peripheral tissues via lipoproteins and to store excess energy long-term,
respectively [10, 32, 33]. Intramitochondrial citrate derived from glycolysis is transported
to the cytoplasm where ER-bound ATP citrate lyase cleaves citrate to acetyl-CoA and
oxaloacetate [11]. In the cytosol, a series of coordinated decarboxylative condensation
reactions occur in which acetyl-CoA is converted into malonyl-CoA by acetyl-CoA
carboxylase (ACC) [11]. Malonyl-CoA is subject to subsequent elongation reactions
catalyzed by the multi-subunit fatty acid synthase (FAS), ultimately generating 16- and
18-carbon saturated fatty acids [11]. In the cytosol, acyl-CoA synthetase activates fatty
acids to acyl-coenzyme esters to enable their entry into lipid synthesis or fatty acid
oxidation [34].
The fatty acyl-CoA chains used for triglyceride synthesis originate from de novo
lipogenesis or from adipose tissue lipolysis [32]. Triglyceride synthesis occurs through
the glycerol phosphate pathway in most tissues or the monoacylglycerol pathway, where
the latter is quantitatively more important within enterocytes. The enzyme glycerolphosphate acyl transferase (GPAT) catalyzes the addition of fatty acyl-CoA to glycerol3-phosphate, producing lysophosphatidic acid [11]. Next, lysophosphatidic acid is
acylated by one of several acyl-CoA:lysophosphatidic acid acyltransferases to produce
phosphatidic acid, which is then dephosphoylated to generate diacylglycerol (DAG). The
final acyl-CoA is added to DAG by diacylglycerol acyl transferase (DGAT), forming a

14

triglyceride molecule [11]. The resulting triglycerides are either stored as CLDs or are
used for VLDL assembly (liver) or chylomicron assembly (intestine) [11].

1.3.2

Cholesterol synthesis and esterification

Cholesterol is an essential 27-carbon steroid present in the membranes of all mammalian
cells and is involved in bile salt and steroid hormone synthesis [35]. The first step in
cholesterol synthesis involves the enzymatic combination of acetyl-CoA with
acetoacetyl-CoA to form 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA). HMGCoA is reduced to mevalonate by HMG-CoA reductase, the rate-limiting step in
cholesterol biogenesis and the target for statin drugs. Through a series of phosphorylation
and condensation reactions, mevalonate is converted to a 30-carbon squalene molecule
[35]. The cyclization of squalene yields lanosterol, which after several modifications is
converted to one cholesterol molecule [35]. Cells must maintain cholesterol homeostasis
membrane proteins functioning, however, too much cholesterol causes membrane
toxicity. Therefore, free cellular cholesterol is converted to cholesterol ester by addition
of acyl-CoA (primarily olelyl-CoA) catalyzed by ACAT for storage in CLDs or addition
to the core of chylomicrons or VLDL particles [36].

1.3.3

Regulation of triglyceride and cholesterol synthesis

Dietary and endogenous pathways provide lipids for energy, cellular membrane
components and precursor molecules [37]. To maintain energy homeostasis, the synthesis
of lipids is tightly regulated by allosteric and transcriptional control.

1.3.3.1

Regulation of de novo lipogenesis

Sterol regulatory element binding proteins (SREBPs) coordinate fatty acid and
cholesterol synthesis [38]. The SREBP family consists of SREBP-1a, SREBP-1c (both
produced from SREBP-1) and SREBP-2 (produced from SREBP-2) isoforms [38]. The
N-terminal domain in SREBP proteins is a basic-helix-loop-helix-leucine zipper (BHLHZip) structure responsible for DNA binding and activation of transcription [38]. These
proteins also contain 2 hydrophobic membrane-spanning sequences and a regulatory Cterminal domain [38]. Normally, the precursor forms of SREBP remain bound to the
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endoplasmic reticulum membrane through the actions of SREBP cleavage-activating
protein (SCAP) and insulin-induced gene (INSIG), forming an INSIG-SCAP-SREBP1
complex [11]. When stimulated by insulin signaling or by low cellular sterol levels,
conformational changes in SCAP cause INSIG to dissociate from the SCAP-SREBP
complex, thereby enabling transport of the SCAP-SREBP precursor complex from the
ER to the Golgi [11]. Golgi site 1 and 2 proteases (SIP/S2P) cleave the precursor protein
[11]. The N-terminal active domain is then released and can enter the nucleus to promote
the expression of target genes [37]. SREBP-2 promotes the expression of cholesterogenic
genes, whereas SREBP-1c promotes the expression of lipogenic genes [37]. Insulin, via
mTORC1 (outlined in 1.6.1), induces SREBP-1c activation at the transcriptional level
[37]. Therefore, nutritional status regulates the expression of SREBP-1c. SREBP1c
phosphorylation is promoted by an inhibition of its phosphatase, lipin 1. When activated
by oxysterols, liver X receptor (LXR)α, induces SREBP-1c transcription. Target genes of
SREBP-1c include lipogenic genes FAS, ACC and SCD-1 [37].

1.3.4

Fatty acid oxidation

During fasting, adipose tissue lipolysis of TGs and de novo synthesis pathways can
provide fatty acids for oxidation as a source of energy [34]. Fatty acids undergo oxidation
primarily through β-oxidation in the mitochondrial matrix. Short- and medium- chain
fatty acids pass directly through the mitrochondrial membrane [32]. Longer acyl-CoA
molecules, however, cannot penetrate the mitochondrial membrane [34] and require
carnitine palmitoyltransferase 1 (CPT-I) to convert them to acyl-carnitine molecules for
transport across the mitochondrial membrane [32, 34]. Once within the matrix, CPT-II
converts long chain fatty acids to their acyl-CoA form [32]. β-oxidation consists of 4
enzymatic steps, where each cycle releases acetyl-CoA that can be used for the
tricarboxylic acid cycle [34]. Furthermore, electrons are transferred from the fatty acylCoA to reduce flavin-adenine dinucleotide (to FADH2) and to the oxidized form of
nicotinamide-adenine dinucleotide (to NADH) [32, 34]. These coenzymes donate
electrons to the electron transport chain to drive ATP synthesis [32].
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1.3.4.1

Regulation of fatty acid oxidation

To prevent simultaneous oxidation and synthesis of fatty acids within a cell, malonylCoA, the product of the first step of de novo fatty acid synthesis, is an allosteric inhibitor
of CPT-I activity [32]. Fatty acid oxidation is also controlled at the transcriptional level
by a class of ligand-activated receptors, peroxisome proliferator-activated receptors
(PPARs) [34]. The presence of fatty acids activates PPARs, which then dimerize with
retinoid X receptor (RXR), a nuclear receptor [34, 39]. This heterodimer then binds to
PPAR response elements (PPREs) in the promoter of target genes [34]. The PPAR family
includes PPARα, PPARβ⁄δ and PPARγ. PPARα controls fatty acid oxidation gene
expression in the liver whereas PPARβ⁄δ control those in the skeletal muscle and heart
[34]. PPARγ is highly expressed in the intestine [40].

1.4

Insulin signaling

Insulin is the central hormone involved in nutrient-metabolism communication. Under
normal conditions, dietary glucose stimulates insulin secretion from pancreatic β-cells
into the circulation to promote glucose uptake into muscle and adipose tissue, protein and
glycogen synthesis in muscle and liver as well as lipogenesis and lipid storage in the liver
and adipose tissue [11, 18-20]. Concomitantly, insulin signaling inhibits lipolysis of TGs
stored in adipose tissue, suppresses hepatic gluconeogenesis and glucose secretion, and
inhibits fatty acid oxidation [21].
The insulin receptor is a plasma membrane glycoprotein consisting of an extracellular αsubunit and a transmembrane β-subunit with tyrosine kinase activity. The binding of
insulin to the α-subunit first triggers receptor dimerization, forming an α2 β2 complex,
and second, autophosphorylation of the β-subunit [19]. The active insulin receptor
recruits and phosphorylates several substrates that lead to the activation of two important
signaling cascades; namely, the mitogen-activated protein kinase (MAPK) pathway and
the phosphoinositide 3-kinase (PI-3K) pathway [19]. The MAPK cascade mediates
insulin-stimulated mitogenesis and cellular growth, whereas the PI-3K cascade mediates
insulin-stimulated metabolism [19].
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Insulin-stimulated activation of PI-3K produces phosphatidylinositol (3,4,5)-triphosphate
(PIP3), a secondary messenger, which activates 3-phosphoinositide-dependent protein
kinase-1 and -2 (PDK1 and PDK2) [19]. PDK1 and PDK2 phosphorylate Akt at tyrosine308 and serine-473, respectively, leading to complete Akt activation [19]. Akt activates
downstream targets including forkhead box protein O1 (FoxO1) and mammalian target of
rapamycin complex 1 (mTORC1) [18]. FoxO1 is a transcription factor that activates
gluconeogenesis. Insulin-stimulated phosphorylation of FoxO1 prevents its translocation
from the ER to the nucleus, thereby downregulating genes required for gluconeogenesis,
such as glucose 6 phosphate [11, 20]. Activation of mTORC1 by phosphorylated Akt
indirectly promotes the expression and nuclear localization of SREBP-1c, the
transcription factor that activates de novo lipogenesis [19, 20]. Together, Akt acts as the
fork in the gluconeogenic and lipogenic branches of insulin signaling (Figure 1).
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Figure 1-2 Insulin signaling in an insulin sensitive liver.
In normal cells, insulin binds to and activates the insulin receptor (IR), resulting in
receptor autophosphorylation and subsequent tyrosine phosphorylation of IR substrates
(IR1/2). This initiates further downstream signals including activation of the serine kinase
Akt via PI3K. Phosphorylation of mTORC1 by Akt induces activation of SREBP-1c, the
master regulator of genes involved in fatty acid and triglyceride synthesis (de novo
lipogenesis, DNL). Insulin activated Akt also stimulates the phosphorylation of FoxO1,
resulting in its exclusion from the nucleus and subsequent prevention of the upregulation
of genes involved in (i) gluconeogenesis (PEPCK, G6Pase) and (ii) VLDL formation
(MTP).
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1.4.1

Insulin resistance

Resistance to the physiological actions of insulin results in impaired anabolic glucose
metabolism and pro-atherogenic dyslipidemia [22, 23]. Insulin resistance is a central
feature of MetS and type 2 diabetes, where insulin-resistant subjects display
hyperinsulinemia, hyperglycemia and hypertriglyceridemia. In an effort to achieve
insulin action in peripheral tissues, pancreatic β-cells expand and proliferate, resulting in
hyperinsulinemia, a primary instigator to type 2 diabetes and cardiovascular dysfunction
[19].

1.4.1.1

Hepatic insulin resistance

Sources of uncontrolled blood glucose are 2-fold: reduction of blood glucose uptake from
the circulation and impaired suppression of hepatic gluconeogenesis [23]. Impaired
suppression of gluconeogenesis is due to an upregulation of transcription factor, FoxO1
(lack of phosphorylation) in the liver. While the FoxO1 pathway becomes insulin
resistant, insulin sensitivity is maintained in the mTORC1 pathway and is over-stimulated
in the context of hyperinsulinemia [20]. As a result, SREBP-1c expression and activation
are extremely high and fatty acid synthesis is accelerated [20]. Thus, excess triglycerides
from hepatic de novo and ectopic sources cause an increase in hepatic VLDL assembly
and secretion. This dichotomy was coined "selective insulin resistance" by Goldstein and
Brown in 2008 and is likely explained by the divergence of insulin signaling downstream
of Akt [20].
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Figure 1-3 Insulin signaling in an insulin resistant liver.
During the hyperinsulinemic state associated with insulin resistance, the mTORC1
pathway remains sensitive to insulin, thereby amplifying SREBP-1c-mediated de novo
lipogenesis. By contrast, Akt fails to phosphorylate FoxO1. As such, FoxO1 remains in
the nucleus and upregulates the transcription of MTP (promotes VLDL formation),
PEPCK and G6Pase (promote gluconeogenesis).
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1.4.1.2

Insulin resistance in peripheral tissues to the liver

Obesity-induced over-expansion of adipose tissue induces hypoxia, triggering an
inflammatory response and subsequent insulin resistance. As such, impaired insulin
signaling at the level of the insulin receptor reduces glucose uptake in adipose tissue and
downregulates cell surface expression of the major insulin-responsive glucose
transporter, GLUT4 [23, 24]. In skeletal muscle, insulin signaling at the level of the
receptor is also impaired and reduced glucose uptake is due to a reduction of GLUT4
translocation, docking or fusion to the surface of muscle cells [24].
Liver-derived hyperglycemia coupled with chronic hyperinsulinemia is thought to further
impair insulin's ability to inhibit adipose tissue lipolysis [23]. As such, insulin-resistant
adipocytes release higher levels of free fatty acids (FFAs), which accumulate in other
tissues such as the liver thereby providing glycerol as a substrate for gluconeogenesis and
FA substrate for triglyceride synthesis, VLDL production and hepatic lipid storage [21,
23]. Furthermore, lipotoxicity resulting accumulation of ectopic fat derived from
adipocyte lipolysis potentiates insulin resistance to other tissues [21, 23]. Finally, the
increased production of cytokines by expanded adipose tissue reduces LPL expression,
which contributes to hypertriglyceridemia observed in MetS [25].

1.4.1.3

Evidence for intestinal insulin resistance

In chow-fed hamsters and normal humans, insulin acutely inhibits intestinal apoB48
secretion [26, 27]. By contrast, acute elevations in plasma FFAs in hamsters and humans
stimulates intestinal lipoprotein production [22]. Therefore, insulin-mediated suppression
of plasma FFA, and the lack thereof in the setting of insulin resistance, effectively
highlights the emerging concept that non-dietary sources of FA are important substrates
for intestinal TG storage or TG-containing lipoprotein secretion. The influence of
peripheral insulin resistance on intestinal-TG secretion is further displayed in insulinresistant subjects and fructose-fed hamsters, where an overproduction of triglyceride-rich,
apoB48-containing chylomicrons is observed, resulting in increased and prolonged
postprandial lipemia [22, 28]. Moreover, fasting plasma insulin positively correlates to
postprandial TG, large VLDL particles and chylomicron remnants [29].
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Evidence for an intestinal specific resistance to insulin has also been documented.
First, intestinal de novo lipogenesis does occur, and its activity positively correlates with
intestinal expression of Srebf-1c [22]. Increased de novo lipogenesis was reported in
primary enterocytes from fructose-fed hamsters [29]. In the same experiment, inhibition
of fatty acid synthase decreased fasting apoB48 lipoprotein secretion [29]. Abnormal
insulin signaling in insulin-resistant hamster enterocytes has also been observed; namely,
decreased insulin receptor substrate activation, reduced Akt protein, increased PTP-1B
protein and activated ERK1/2 [26]. The intestine has also been shown in rats to
contribute to endogenous glucose production via gluconeogenesis, which is rapidly
inhibited by insulin infusion [30]. Furthermore, the expression of gluconeogenic genes in
the rat small intestine, such as glucose 6 phosphate, is strongly induced in fasting and
diabetic states [31]. The bifurcation in insulin sensitivity or selective insulin resistance
that has been well documented in the liver remains to be explored in the insulin-resistant
intestine.

1.5

Nutrient signaling in the gut

Glucagon like peptide-1 (GLP-1 and glucose dependent insulinotropic polypetide (GIP)
are incretin hormones secreted from the intestinal L-cells and K-cells, respectively, in
response to glucose ingestion [41]. They activate their respective G protein coupled
receptors, namely, the GLP-1 receptor (GLP-1R) and the GIP receptor (GIPR) to
stimulate insulin secretion from pancreatic β-cells to ensure efficient glucose disposal
[41]. In healthy humans, GLP-1 and GIP are responsible for 50-70% of glucosestimulated insulin secretion [42]. Dipeptidyl peptidase 4 (DPP4) is a circulating serine
protease, also secreted from intestinal cells that truncates GLP-1 and GIP, rendering them
biologically inactive [41]. DPP4 is therefore an important regulator of energy
homeostasis.
In the setting of type 2 diabetes (T2DM), the incretin effect of glucose-stimulated insulin
secretion is significantly reduced; as such, DPP4 inhibitors are widely used to potentiate
GLP-1 and GIP action [41]. Similarly, GLP-1R agonists are approved therapies for type 2
diabetes. In T2DM cardiovascular safety trials, GLP-1R agonists were found to elicit
significant decreases in major adverse cardiovascular events, partly due to GLP-1-
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mediated benefits on both fasting and postprandial lipid profiles [43]. In addition to
nutrient-dependent insulin secretion, GLP-1 regulates postprandial lipid and lipoprotein
metabolism. The posttranslational processing of the proglucagon gene in intestinal L cells
in response to nutrient ingestion not only yields GLP-1, but also glucagon-like peptide 2
(GLP-2) [43]. Moreover, GLP-1 and GLP2 are co-secreted from intestinal L-cells in a 1:1
molar ratio when stimulated [4, 43]. These two hormones have opposing effects on
metabolism, where GLP-1 lowers glycemia and post-prandial plasma chylomicron
triglycerides and GLP-2 increases intestinal fat absorption and chylomicron-triglyceride
secretion into plasma [44, 45]. While GLP-2 does not possess insulinotropic activity,
GLP-2 promotes intestinal growth and enhances gut barrier function [42, 46]. As such,
GLP-2R agonists have been successfully used to treat patients with short bowel syndrome
[4, 42].
The opposing roles of GLP-1 and GLP-2 on intestinal lipoproteins are not fully
understood [4]. Despite being secreted in a 1:1 molar ratio, the degradation of GLP-1 and
GLP-2 by DPP4 occurs at different rates, where the former has a half-life of 1.5 min and
latter has a half-life of 7 min [43]. This level of complexity further challenges our
understanding on how GLP-1 and GLP-2 regulate postprandial lipid metabolism.
Furthermore, many of the described effects of these hormones were observed at
pharmacological doses. As nutrients are potent stimulators of gut hormone secretion,
nutraceuticals may prove to be attractive therapeutics for potentiating GLP-1 and GLP-2
action [47].

1.6

Flavonoids

Phytochemicals are abundant in nature; of these, flavonoids are of increased interest due
to their significant biological benefits [48]. Flavonoids accumulate in the stems, flowers,
leaves and fruits of plants and are involved in pigmentation, UV filtration, nitrogen
fixation and antimicrobial properties [48]. Flavonoids are the most abundant polyphenol
in the human diet; they are found in soy, fruits, vegetables, nuts, seeds, cocoa, coffee,
wine and tea [49]. It is estimated that the average North American or European ingests is
between 20 and 70 mg of flavonoids per day [48]. Their 15-carbon atom structures
include three phenolic rings bound to one or more hydroxyl groups [49]. Their structure
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and degree of oxidation divides them into 6 classes; namely, flavonols, flavones,
isoflavones, flavanones, flavan-3-ols and anthocyanidins [50]. If glycosylated, hydrolysis
occurs at the brush-border of the small intestine and the released lipophilic aglycone
enters enterocytes by passive diffusion [51]. Here, aglycones are metabolized and their
products enter portal circulation for phase II metabolism in the liver, however substantial
quantities of absorbed aglycones pass from the small to the large intestine [51]. Here,
colonic microbiota hydrolyze aglycones and these products can also be absorbed into the
portal circulation. Flavonoid metabolites that are excreted in urine or in bile, however,
often exceed those that enter circulation [51]. Therefore their abundance and
bioavailability may limit their therapeutic potential, thus making purified forms of
flavonoids attractive agents for investigation.

1.6.1

Citrus flavonoids and cardiovascular risk

Flavonoid structure enables their roles as reducing agents, hydrogen-donating
antioxidants and oxygen quenchers: attractive features in a MetS setting [49].
Epidemiologically, a higher intake of flavonoids correlates with a lower cardiovascular
risk [49]. In particular, citrus fruits represent a significant source of many types of
flavonoids and intake has been associated with a reduction in cardiovascular events [49].
Citrus flavonoids represent approximately 10 mg of the previously mentioned average
daily flavonoid intake [49]. Polymethoxylated flavones including tangeretin, nobiletin
and sinensetin are most abundant in the pith and peels of citrus fruits [49]. Drinking one
glass of orange juice per day reduces the risk of stroke in men by 25%. In 69,622 female
nurses, a 19% reduction in ischemic stroke risk was found in subjects with high
flavanone intake through orange and grapefruit juices and fruits [49]. Together, multiple
beneficial effects of citrus flavonoid consumption have been shown, however, their
mechanisms of action are not completely established.

1.6.2

Nobiletin

This thesis focuses on a tangerine-derived, polymethoxylated flavonoid, nobiletin.
Several earlier studies from our group and others have investigated the role of nobiletin in
modulating lipid metabolism, glucose homeostasis and lipid metabolism. In HepG2 cells,
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nobiletin robustly attenuated apoB100 secretion in a similar manner to insulin. Nobiletin
increased LDLR expression and activity and decreased MTP and DGAT1/2 mRNA
through the mitogen-activated protein kinase-extracellular (MAPK/ERK) signal-related
kinase signaling pathway [52]. Unlike insulin, however, nobiletin did not induce
phosphorylation of the insulin receptor or insulin receptor substrate-1. Importantly,
nobiletin did not stimulate lipogenesis [52]. An unbiased chemical screen identified
nobiletin as a clock-amplitude-enhancing small molecule [53]. In HepG2 cells, nobiletin
modulated the AMPK-Sirt1 signaling pathway to prevent palmitate-induced lipogenesis
in a Bmal1-dependent manner. Moreover, nobiletin attenuated secretions of reactive
oxygen species induced by palmitate treatment [54].
Several studies have investigated the metabolic protection of nobiletin in vivo. A
combination of tangeretin and nobiletin treatment improved glucose tolerance in
hyperinsulinemic and hypercholesterolemic hamsters [55]. Nobiletin treatment to dietinduced obese mice as well as in db/db mutant mice improved metabolic indices and
increased energy expenditure in a Clock gene-dependent manner [53]. Retinoic acid
receptor-related orphan receptors (ROR) were identified as direct targets of nobiletin
[53]. In Ldlr-/- mice with diet-induced obesity, intervention by supplementation of
nobiletin to a HFHC diet reversed existing obesity through enhanced energy expenditure
and increased hepatic fatty acid oxidation [9]. Furthermore, nobiletin improved insulin
sensitivity and hyperlipidemia in these mice [56]. In Ldlr-/- mice, supplementation of
nobiletin to a high-fat Western-style diet prevented obesity, increased glucose tolerance
and dramatically attenuated atherosclerosis. Nobiletin also prevented hepatic triglyceride
accumulation by enhancing hepatic-fatty acid oxidation, interestingly, without activating
any peroxisome proliferator-activated receptors (PPARs). Furthermore, nobiletin
attenuated dyslipidemia by reducing VLDL-triglyceride secretion from liver into plasma
[52]. This reduction in reduced VLDL-triglyceride secretion was attributed to nobiletin's
ability to limit lipid accumulation in both the liver and the intestine. Of significance for
this thesis, significant levels of triglyceride mass remained in the intestine of Western-fed
mice following a 6 hour fast but not in mice fed the same Western diet supplemented
with nobiletin [52]. The reasons for this effect are unknown. Therefore, the present
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studies investigated the mechanism(s) through which nobiletin prevents high-fat dietinduced fasting intestinal triglyceride accumulation.

1.7
1.7.1

In vivo models used
Mouse models

Mice transport the majority of their plasma cholesterol on HDL particles, rendering them
relatively resistant to cardiovascular disease [57]. Therefore, genetic and dietary
manipulations of their lipid metabolism are required to study metabolic syndrome. The
C57BL/6J mouse substrain is often used in metabolic studies, as they are susceptible to
diet-induced diabetes and obesity [17]. Mice deficient of the receptor that clears
atherogenic LDL and VLDL particles, Ldlr-/- mice on a C57BL/6J background, develop
moderate hypercholesterolemia and display a shift to elevated LDL cholesterol, similar to
a human lipoprotein profile [57, 58]. These parameters are further increased when placed
on a diet with containing greater than 20% kcals from fat, whereby they develop severe
hyperlipidemia, become obese, display insulin resistance and develop extensive
atherosclerosis, [58]. These features make Ldlr-/- mice a useful model for studying
obesity and insulin resistance in the presence of dyslipidemia.

1.7.2
1.7.2.1

Mouse diets
Chow diet

Laboratory chow (TD8604) was used as a control diet for metabolic indices altered by a
high-fat, high-cholesterol diet. The chow diet contains complex carbohydrates and has a
caloric density of 3.0 kcal/g (14% of calories come from fat). The chow diet was fed ad
libitum to mice in all studies.

1.7.2.2

High-fat, high-cholesterol diet

The high-fat, high-cholesterol diet (HFHC) (TD09268) was used to induce obesity,
hyperlipidemia and insulin resistance. Other studies in our lab used this diet to induce
atherosclerosis [9,52]. The HFHC diet is composed of anhydrous milk fat and lard (58%
saturated, 36% monounsaturated and 5% polyunsaturated fatty acids) and has a caloric
density of 4.5 kcal/g (42% of calories come from fat). The carbohydrate sources are
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sucrose (30% of calories) and corn starch (13% of calories), whereas the protein source is
casein (15.2% of calories). The HFHC diet was fed ad libitum to the mice in all studies.
Table 2.1 Mouse diets

Formula

Traditional Chow Diet
TD8604

High-fat, Cholesterol
Containing Diet
(TD09268)
g/kg

Casein

*See represented
ingredients, exact
amounts not specified

195

DL-Methionine
Sucrose

3
341.46

Corn Starch

150.75

Anhydrous Milk Fat

160

Lard (Pork)

50

Cellulose

35.13

Mineral Mix

50

Zinc Carbonate

0.04

Vitamin Mix

10

Choline Bitartrate

3

Ethoxyquin

0.02

Macronutrients
Protein

24.3 (32)

17.3 (15.2)

Carbohydrate

40.2 (54)

48.7 (42.8)

Fat

4.7 (14)

21.2 (42)

kcal/g

3.0

4.5

Cholesterol (%wt)

0.005%

0.2%

*Represented ingredients: Dehulled soybean meal, wheat middlings, flaked corn,
ground corn, fish meal, cane molasses, ground wheat, dried whey, soybean oil,
brewers dried yeast, dicalcium phosphate, calcium carbonate, iodized salt, choline
chloride, kaolin, magnesium oxide, ferrous sulfate, vitamin E acetate, menadione
sodium bisulfite complex (source of vitamin K activity), manganous oxide, copper
sulfate, zinc oxide, niacin, thiamin mononitrate, vitamin A acetate, vitamin D3
supplement, calcium pantothenate, pyridoxine hydrochloride, riboflavin, vitamin B12
supplement, calcium iodate, folic acid, biotin, cobalt carbonate.

30

1.8

Hypothesis and scope of thesis

Insulin resistance, a central component of MetS, is associated with increased VLDL
production, HDL-cholesterol is decreased and LDL-cholesterol is increased, therefore
posing a significant atherogenic risk. The dichotemy was coined "selective insulin
resistance" in the liver by Goldstein and Brown in 2008, and helps to explain
hyperglycaemia, hyperinsulinaemia and hypertriglyceridemia present in type 2 diabetes
patients [20]. Although selective insulin resistance has been well documented in liver, it
is possible that this also occurs in the intestine in insulin resistant states. Emerging
evidence demonstrates that insulin-resistant subjects also overproduce triglyceride-rich,
apoB48-containing chylomicrons, resulting in increased postprandial lipemia. While
statin therapy aims to control LDL-cholesterol concentrations, postprandial
hypertriglyceridemia continues to drive atherogenicity [59, 60], suggesting a further
understanding of how dysregulated of intestinal lipoprotein metabolism contributes to
plaque development is required.
Supplementation of nobiletin to a high-fat, high-cholesterol (HFHC) diet in Ldlr-/- mice, a
physiological model of MetS, prevents obesity, insulin resistance, hepatic steatosis,
dyslipidemia and atherosclerosis, in part, through enhanced hepatic-fatty acid oxidation
[52]. These previous studies were performed with a primary focus on the liver. The small
intestine, however, is the first site of regulation of dietary fat and cholesterol;
consequently, abnormal intestinal lipid metabolism could also promote MetS
development, especially through its role in postprandial lipemia. Therefore, the small
intestine represents a potential site of protection by nobiletin. Due to the evidence that
hormonal and nutritional signals play a role in the initiation of intestinal lipoprotein
formation [4], the purpose of these studies was to examine the metabolic effects of
feeding both male and female mice a HFHC diet on the development of intestinal insulin
resistance, intestinal lipid accumulation, postprandial chylomicron secretion and gut
peptide secretion. Furthermore, the potential therapeutic effects of nobiletin to prevent
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HFHC diet-induced dysregulation of intestinal lipoprotein metabolism were explored.
Moreover, the ability of nobiletin to exert its preventative effects through GLP-2
signalling, was investigated.
This thesis will address the following hypothesis:
Nobiletin prevents fasting jejunal lipid accumulation by correcting intestinal insulin
signalling and enhancing intestinal triglyceride secretion into plasma.
The specific aims of this thesis are as follows:
Aim 1: Determine if nobiletin corrects intestinal insulin resistance.
Aim 2: Determine if nobiletin improves oral glucose tolerance via intestinal incretin
secretion.
Aim 3: Determine if nobiletin alters the rate at which chylomicrons are secreted into
plasma.
Aim 4: Determine if reductions is intestinal triglyceride content by nobiletin are mediated
by GLP-2.
Aim 4: Determine if nobiletin protects female mice from HFHC diet-induced metabolic
perturbations.
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Chapter 2

2

Nobiletin corrects intestinal insulin resistance and lipid
metabolism in Ldlr-/- mice fed a high-fat diet
2.1

Introduction

Excess energy intake relative to energy expenditure drives the abnormalities that
encompass the metabolic syndrome (MetS) - namely, obesity, insulin resistance,
atherogenic dyslipidemia and hypertension [1]. Insulin resistance, a central component of
MetS, is characterized by a decrease in insulin-stimulated glucose transport and
metabolism in adipocytes and skeletal muscle as well as impaired suppression of glucose
output, causing hyperglycemia. Furthermore, hyperinsulinemia associated with insulin
resistance causes increases in triglyceride (TG) synthesis from de novo lipogenesis. As a
result, insulin resistance is associated with increased hepatic VLDL production, HDLcholesterol is decreased and LDL-cholesterol is increased [2].
Although insulin resistance has been well documented in liver, it is possible that this also
occurs in the intestine in insulin resistant states. Emerging evidence demonstrates that
insulin-resistant subjects also overproduce triglyceride-rich, ApoB 48-containing
chylomicrons, resulting in increased postprandial lipemia [3, 4]. Postprandial
hypertriglyceridemia is now recognized to play a prominent role in the pathogenesis of
atherosclerosis [2, 5], highlighting the importance of understanding the molecular
regulation of intestinal lipoprotein metabolism. Furthermore, there is a growing need for
novel therapeutics that target intestinal lipid metabolism.
Intestinal enterocytes are responsible for absorbing and packaging lipids for
storage in cytoplasmic lipid droplets (CLD) or in chylomicrons for distribution
throughout the body. Furthermore, the number and size of CLDs in mouse enterocytes
correspond to the fat content of the diet [6]. The presence of nutrients in the small
intestine stimulates intestinal L-cells to secrete hormones glucagon-like peptides 1 and 2
(GLP-1 and GLP-2) [7]. These two hormones have opposing effects on metabolism,
where GLP-1 lowers glycemia and post-prandial plasma chylomicron triglycerides [8]
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and GLP-2 increases intestinal fat absorption and chylomicron-triglyceride secretion into
plasma [9]. As such, both have been exploited pharmacologically: GLP-1 receptor (GLP1R) agonists are widely used as treatments for patients with T2DM and GLP-2 receptor
agonists have been successfully used to treat patients with short bowel syndrome [7].
Epidemiologically, higher intake of flavonoids correlates with lower cardiovascular risk
[10]; nobiletin is a tangerine-derived flavonoid with significant therapeutic potential [10].
Supplementation of nobiletin to a high-fat, high-cholesterol (HFHC) diet in Ldlr-/- mice,
a physiological model of MetS, prevents obesity, insulin resistance, hepatic steatosis,
dyslipidemia and atherosclerosis, in part, through enhanced hepatic-fatty acid oxidation
[11]. While these studies provide insight into the metabolic effects of nobiletin, they
primarily focus on the liver, providing limited understanding of the protective role of
nobiletin on the small intestine. Intriguingly, Ldlr-/- mice fed a HFHC diet, but not chow,
retain lipids in the jejunum of the small intestine, even in the fasted state. The addition of
nobiletin to the HFHC diet completely prevents this fasting jejunal lipid accumulation,
which may be related to nobiletin-induced enhanced insulin sensitivity. Due to the
evidence that hormonal and nutritional signals play a role in the initiation of intestinal
lipoprotein formation [7], the purpose of these studies was to examine the metabolic
effects of feeding both male and female mice a HFHC diet on the development of
intestinal insulin resistance, intestinal lipid accumulation, post-prandial chylomicron
secretion and gut peptide secretion. Moreover, the potential therapeutic effects of
nobiletin to prevent HFHC diet-induced dysregulation of intestinal lipoprotein
metabolism were explored.

2.2
2.2.1

Materials and methods
Animals and diets

Male and female Ldlr-/- mice on a C57BL/6 background (Jackson Laboratory, Bar
Harbor, MA), were housed in pairs in standard cages at 23˚C on a 12 h light and dark
cycle. The animals were cared for in accordance with the Canadian Guide for the Care
and Use of Laboratory Animals. All experimental procedures were approved by the
Animal Care Committee at Western University (protocol # AUP-2016-057). Mice 10-12

40

weeks of age (n=16) were fed ad libitum, a purified rodent chow diet (14% of calories
from fat, Teklad Rodent Diet 8604, Envigo, Madison WI) for 10-12 weeks. Another
group of mice (10-12 weeks of age, n=16/group) were fed a high-fat, high cholesterol diet
(HFHC; 42% calories from fat, 0.2% cholesterol, Teklad TD 09268, Envigo, Madison,
WI) for 10-12 weeks. The third group of mice (10-12 weeks of age, n=16/group) were
fed the HFHC-diet supplemented with 0.3% nobiletin (#10236-47-2, R&S PharmChem,
Hangzhou City, China). Food intake and body weight measured weekly. Caloric intake
was calculated as weight of food eaten (g) per day multiplied by the caloric content of
each diet (chow 3.0 kcal/g; HFHC 4.5 kcal/g). We previously observed a taste aversion
with nobiletin, which was mitigated by increasing the flavonoid dose by 0.1% every two
days until 0.3% was achieved in order to prevent significant impact on food intake (data
not shown).

2.2.2

Blood and tissue collection

Mice were fasted for 6 hours at the start of the light cycle prior to blood taking or
sacrifice. Blood was collected via saphenous vein for fasting and post-gavage samples. At
sacrifice, animals were euthanized by CO2 inhalation and blood was collected via cardiac
puncture in syringes containing 80µL of 7% Na2-EDTA. Blood was centrifuged at 12
000 rpm for 10 minutes at 4˚C to separate plasma, which was stored at -20˚C for further
use. Tissue dissections were performed via midline incision. Pancreata were removed,
weighed and fixed in 4% paraformaldehyde and paraffin-embedded for histological
analyses. The entire small intestine (~36cm) was excised and cut in 3 pieces at a 1:3:2
ratio (duodenum:jejunum:ileum). Pieces were flushed with 0.5 mM sodium taurocholate
warmed to 37˚C, ectopic fat was removed, segments were flushed with saline at 4˚C. The
first piece of each section of the small intestine was cut and placed in optimum cutting
temperature (OCT) medium, frozen on dry ice and stored at -80˚C for histological
analyses. Jejunal epithelial cells were scraped and frozen on dry ice for mRNA and lipid
measurements. Liver, epididymal white adipose tissue (eWAT), inguinal white adipose
tissue (iWAT) or parimentrial white adipose tissue (pWAT) were removed, weighed and
snap-frozen in liquid N2 and stored at -80˚C.
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2.2.3

Glucose tolerance test

A glucose tolerance test was performed following a 6 hour fast by administering 15%
glucose in 0.9% NaCl (1g/kg body weight) by oral gavage or i.p. injection [12]. Blood
samples for glucose measurements (Bayer Contour Blood Glucose Monitoring System,
Bayer Healthcare) were taken up to 120 minutes post-glucose load. Glucose tolerance
was calculated as a delta from baseline. Blood samples for plasma insulin measurements
(Elisa) were taken up to 60 minutes. Plasma insulin was determined in EDTA-plasma
samples, stored at -20˚C, by mouse specific ELISA (ALPCO Diagnostics, Salem, NH:
mouse ultrasensitive ELISA #80-INSMSU-E01).

2.2.4

Postprandial triglyceridemic response

Food was removed for 6 h at the start of the light cycle, mice were injected with
poloxamer-407 (i.p.) to block catabolism of lipoproteins. 30 min later, a 200 µl olive oil
gavage was administered and blood collected at baseline and up to 4 h post-gavage. No
food was available during the time course.

2.2.5

Tissue lipids

Intestinal segments and liver lipids were extracted from ~80-100mg of tissue obtained at
sacrifice using the method of Folch et al, from samples stored at -80˚C, as described
previously [13, 14]. For quantification of TG, FC and TC in tissues, [3H] Cholesterol
oleate (Amersham Canada Ltd, Oakville, ON, Canada) were added to assess recovery.
Samples and standards were dried under N2, and a 1% Triton X-10 solution in
chloroform was added and left at room temperature for 1 hour to solubilize. Samples and
standards were dried under N2, followed by the addition of deionized water and
incubation at 37˚C for 15 minutes. Samples were analyzed using enzymatic reagents for
triglyceride (Roche Diagnostics: Triglyceride/glycerol blanked, #11877771 216), total
cholesterol (WAKO Diagnostics: Cholesterol E (CHOD-DAOS method) #439-17501)
and free cholesterol (WAKO Diagnostics: Free cholesterol (CHOD-DAOS method)
#439-17501). Cholesteryl ester was determined as the difference between total
cholesterol and free cholesterol.
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2.2.6

Plasma measurements

Plasma triglyceride and total cholesterol was measured on Cobas Mira S autoanalyzer
(Roche Diagnostics, Laval, Canada) using calibrators and controls from Roche
Diagnostics [12]. Enzymatic reagents for triglyceride (Roche Diagnostics:
triglyceride/glycerol blanked #11877771 216) and cholesterol (Roche Diagnostics:
Cholesterol CHOD-PAP #11491458-216) were used. Plasma insulin (ALPCO
Diagnostics, Salem, NH: mouse ultrasensitive ELISA #80-INSMSU-E01) was
determined in EDTA-plasma samples stored at -80˚C. For measurement of active GLP-1
(Mesoscale 150JVC-1) and active GIP (Crystal Chem) blood was mixed with 10% TED
(5,000 KIU/mL Trasylol, 1.2 mg/mL EDTA, 0.1 nmol/L Diprotin A) and plasma stored
at -80˚C until the assay was performed. DPP-4 activity was assessed using a fluorometric
assay (substrate: 10 mM H-Gly-Pro_AMC HBr (Bachem#I-1225), standard: AMC
(Bachem #Q-1025) using 10 µL of plasma (no TED).
Fresh-EDTA plasma (50µL) was separated by fast protein liquid chromatography (FPLC)
using an AKTA purifier and a Superose 6 column [13]. Constant flow rate of 0.4mL/min
was used to collect 500µL fractions. An aliquot of each fraction was used to measure
cholesterol and triglycerides enzymatically in both standards and samples on a microtitre
plate with added enzymatic reagents (Triglyceride: Roche Diagnostics,
triglycerides/glycerol blanked #11877771 216 and total cholesterol: WAKO Diagnostics,
Richmond, VA, Cholesterol E: (CHOD-DAOS method) #439-17501).

2.2.7

Limulus amebocyte lysate assay

Plasma lipopolysaccharide (LPS) concentration was determined using a commercial kit
(GenScript) following the manufacturer's instructions. Briefly, samples (stored at -20 ˚C)
were diluted 1/10 with endotoxin-free water, heated for 10 min at 70 ˚C to minimize
background by contaminating proteins. Limulus amebocyte lysate assay (LAL) reagents
were added to samples and standards, which were then loaded onto a microtitre plate.
Following a 45 min incubation at 37 ˚C, absorbance was read at 545 nm.
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2.2.8

Plasma ultracentrifugation

For fasting samples, plasma of body-weight matched mice were pooled. Lipoproteins
were separated from fresh plasma by ultracentrifugation in a Beckman TLA-120.2
ultracentrifuge using Quick seal tubes #344625 (Beckman Coulter, Mississauga, ON).
Plasma was spun at 17,000 rpm, 12oC, for 30 minutes to isolate the chylomicron fraction
(intestinal contribution). Following chylomicron removal, the subnatant was centrifuged
in a new tube at 40,000 rpm, 12oC for 2 hours to isolate the VLDL fraction (intestinal
and liver contribution).

2.2.9

Plasma immunoblotting

Plasma was diluted 3200-fold in phosphate buffered saline (PBS, 137 mM NaCl, 2.7 mM
KCl, 10 mM Na2PO4, 1.8 mM KH2PO4) containing 1:100 protease (Sigma P8340) and
phosphatase inhibitors (Sigma P5726). Chylomicron and VLDL fractions of plasma were
diluted 32-fold in PBS containing the same protease and phosphatase 1:100 cocktail.
Samples were run in duplicate on 10% SDS-PAGE gels (BioRad #456-1086) and
transferred in a nitrocellulose membrane. Membranes were blocked and incubated with
primary antibodies goat anti-human apoB diluted 1:200 (Midland Bioproducts
Corporation #71307) and goat anti-albumin diluted 1:20 000. Membranes were washed
and incubated with the secondary antibody IRDye® 800CW Donkey anti-Goat IgG
(H+L) #925-32214 (LI-COR Biosciences, Lincoln, NE) . Imaging and quantitation of
membranes was performed using the LI-COR Odyssey Fc (LI-COR Biosciences) and the
LI-COR Image Studio Software 5.0. Plasma apoB48 signal was normalized to albumin
and expressed as a fold change from the signal of a chow-fed mouse 2 hours post-olive
oil gavage.

2.2.10

Tissue immunoblotting

Frozen jejunal and liver samples were homogenized with a wheaton grinder attached to a
power drill in RIPA buffer (Sigma R0278) containing 1:100 protease inhibitors (Sigma
P8340) and phosphatase inhibitors (Sigma P5726) and 1 mM DTT. Lysates were
collected following sonication and centrifugation and protein concentration determination
was performed by Lowry assay as described previously [15]. For mTORC1, Akt and
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FoxO1 proteins, 12.5 µg, 6.25 µg and 50µg of protein were loaded per lane, respectively,
on a 4-15% SDS-PAGE gel (BioRad Canada, Mississauga, ON, #456-1086). In addition
to using molecular weight markers, a liver lysate was run next to the jejunal lysate for
band identification, as the concentrations of signalling molecules are higher in liver.
Proteins were transferred to a nitrocellulose membrane and incubated with primary
antibodies from Cell Signalling (Danvers, MA): total mTOR (#4517), Ser2448 phosphomTOR (#2971), total AkT (#9272), Ser-473 phospho-AkT (#4051), total FoxO1
(#97635) and Ser256 phospho-FoxO1 (#9461). Membranes were washed and incubated
with a secondary antibody from Cell Signaling; anti-Rabbit IgG horseradish peroxidase
(HRP)-linked #7074 or anti-Mouse rabbit IgG HRP-linked #7076. Detection was
determined using enhanced chemiluminescence reagent (Roche Diagnostics) and
quantification performed using an Imaging Densitometer (GS-700; Bio-Rad Laboratories,
Mississauga, ON).

2.2.11

Jejunal fatty acid synthesis

Fatty acid synthesis was measured following an (i.p) injection of [1-14C]-acetate
(Amersham, GE Healthcare, UK). Briefly, mice were injected with 20 µCi of acetic acid
and sacrificed 30 minutes later. Jejunum (500 mg) were extracted in chloroform:methanol
and incorporation of 1-14C acetic acid into fatty acid was performed as described
previously [15].

2.2.12

Jejunal triglyceride synthesis

Triglyceride synthesis was measured by incubating jejunal homogenates with an ACAT
inhibitor (DuP -128) and [14C]oleoyl-CoA (Amersham GE). The reaction was stopped
after 3 minutes by the addition of chloroform-methanol (2:1) and [3H]cholesteryl oleate
(Amersham GE) was used as an internal standard. Lipid extracts were dissolved and
spotted on TLC plates. Spots were developed in petroleum ether/diethyl-ether/acetic acid
(84:15:1) and identified using iodine vapour. The radioactivity in cholesteryl oleate and
triolein spots was determined by liquid scintillation counting [16].
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2.2.13

Jejunal beta-oxidation

Whole jejunum was excised from euthanized mice and placed in homogenizing buffer
(RIPA) on ice. Jejunum was flushed with 4˚C PBS and sucrose-Tris-EDTA buffer at 4˚C
and ectopic fat was removed. Jejunum was threaded onto a zip-tie and opened
longitudinally onto a glass platform on ice and mucosa was scraped using a cover slip.
Mucosa was homogenized in 0.1 M phosphate buffer, pH 7.2 containing 0.25 M sucrose,
10 mM Tris-HCl, 1 mM EDTA, 1 mM dithiothreitol, and 250 µL of protease inhibitor
(Sigma-Aldrich #P8340). Homogenates were gently vortexed and centrifuged for 20
seconds, and a small aliquot was used for protein determination by the Lowry method
[16]. 50 µL of homogenate was incubated in 0.1 M phosphate buffer, pH 7.2, containing
15 mM Tris malonate, 10 mM MgCl2, 0.5 M DTT, 1 mM carnitine, 0.05 mM coenzymeA, 5 mM ATP, 2 µCi of [1-14C]palmitic acid (PerkinElmer: # NEC075H250UC)/mM
and 150 µM unlabeled palmitic acid complexed with 3% fatty acid-free BSA at 37˚C for
1 hour. Reactions were transferred to a collection tube with a filter paper-lined cap
containing 200 µL of 1M perchloric acid and 20 µL of benzethonium chloride for 1 hour.
14CO2 in the filter pads were measured by liquid scintillation counting.

2.2.14

Gene expression

RNA was isolated from whole jejunum or jejunal mucosa using Trizol reagent (Life
Technologies, Mississauga, Ontario, Canada). Reverse transcription of 1 µg total RNA
was performed using the High Capacity Reverse Transcription kit (Applied Biosystems,
ABI, Streetsville, CA) to yield cDNA. Specific mRNA abundances were measured by
quantitative real-time PCR (qRT-PCR) on an ABI ViiA 7 Sequence Detection System
(ABI) according to the manufacturer's instructions. In the jejunum, mRNA quantification
for Srebf1c, Plin2, Atgl, Mttp, Cd36, Dgat2 was determined. 10 ng samples of cDNA
were assayed in triplicate in 10 µL reactions using a standard curve qRT-PCR protocol to
calculate specific mRNA concentrations. Expression levels for each gene were
normalized to Gapdh expression in jejunum or mucosa. With the exception of Srebf1c, all
primer and probe sets used were purchased as TaqMan Assays (ABI). The probe and
primer sequences for Srebf1c were designed from the known murine Srebf1 locus to
determine splice junctions. The intervening intronic sequence was removed and primers
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and probe were designed from the resultant Srebf1c exon1c-exon2 sequence using Primer
Express 2.0 software (ABI). Primers were obtained from Sigma-Genosys and the probes
labeled 5' with 6-carboxyfluorescein (FAM) and 3' with the quencher MGB® were from
ABI. TaqMan assay for mouse Srebf1c: Forward primer: CAGGCCCGGGAAGTCACT'
Reverse primer: GACCACGGAGCATGGATT; Probe: FAMATTTGAAGACATGCTCCA-MGB®.

2.2.15

Tissue histology and immunohistochemistry

Frozen sections (5-10 per jejunum and ileum, 8µm) 100 µm apart were prepared using a
Leica CM 3050S cryostat. Sections from fasted mice were stained with oil red-O and
counterstained with hematoxylin (Sigma-Aldrich). Photomicrographs were obtained
using an Olympus BX51 microscope (Olympus Canada, Richmond Hill, Canada).
Pancreata were fixed in 4% paraformaldehyde for 24 hours, processed, embedded in
paraffin, and sectioned on a Micron HM335E microtome (Thermo Fisher Scientific).
Pancreas sections (2-3 sections per mouse, >150 µm apart) were blocked with mouse on
mouse (M.O.M) blocking reagent (BMK-2202), incubated with 1:500 mouse anti-mouse
insulin antibody (Sigma I2018) and detected with peroxidase-labeled anti-mouse
antibody (Vector Labs, Burlingame CA, USA). A minimum of 10 insulin-positive cells
was required for islet enumeration [17]. Photomicrographs of whole tissue sections were
obtained using a Leica Aperio AT2 slide scanner and villi-length measurements were
performed using ImageScope.

2.2.16

Transmission electron microscopy (TEM)

Mice were anesthetised using inhaled CO2 following a 6-hour fast or 2-hours after a 200
µL oral olive oil gavage. Jejunum was removed and flushed with sodium taurocholate
warmed to 37˚C, ectopic fat was removed and segments were then flushed with 4˚C
saline. Small pieces of the jejunum were fixed in freshly prepared room temperature 1 %
paraformaldehyde and 1 % glutaraldehyde in 0.1M/L phosphate-buffered saline. Samples
were stored in the primary fixative at 4˚C for several days. Sample preparation,
sectioning, staining and visualization was performed at the UWO Biotron by Stephen
Hearn. After rinsing with distilled water, the tissue was pot-fixed in 1 % osmium
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tetroxide in distilled water for 1 hour, then dehydrated in a graded series of ethanol to
remove all water and immersed in 100% acetone. The tissue was then infiltrated for 1
hour with agitation with 50% epon-araldite resin (Electron Microscopy Sciences, Hatfield
PA) in 100% acetone, followed by infiltration with 100% epon-araldite resin for 2 hours
with agitation. The samples were then transferred to embedding molds with fresh resin
and polymerized overnight in a 60˚C oven. Tissues in the resin blocks Thick sections (0.5
µm) were sliced with a Reichert Ultracut ultramicrotome and stained with 1% toludine
blue and examined by light microscopy to confirm tissue orientation. Ultrathin sections
(90 nm) were stained for 1 minute with Reynolds lead citrate. Images were acquired on a
Philips 420 transmission electron microscope equipped with a side mount AMT 4K
megapixel XR41S-B camera (Woburn, MA). The identification of TG in CLDs was
based on previously published studies [6, 18].

2.2.17

Glucagon-like peptide 2 receptor antagonist, GLP-2 (3-33),
treatment

Synthetic mouse GLP-2 (3-33) was purchased from Chi Scientific (Maynard, MA). The
purity (>0.95) and correctness of the structure was confirmed by mass spectrometry and
HPLC analysis. GLP-2 (3-33) dissolved in PBS or PBS (vehicle) were injected
subcutaneously into mice at 11am daily for 14 days following a 10-week feeding period.

2.2.18

Statistical analysis

Data is presented as mean ± SEM. Statistical analyses were performed using Prism Oneway ANOVA with post-hoc Tukey's test for differences between groups at the same
experimental time points except in the case of body weight, which was measured over
time and a 2-way repeated measures ANOVA with post-hoc Tukey's test was used.
Different letters indicated significant differences between diet groups at a particular time
point whereas symbols indicated significant differences from baseline (delta, Δ) between
diet groups. Significance thresholds were P values less than 0.05. An unpaired t-test was
used to test for differences in the fasting-refeeding studies and significant differences
(P≤0.05) are indicated by an asterisk.
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2.3
2.3.1

Results
Nobiletin prevents high-fat, high-cholesterol (HFHC)-diet
induced weight gain

We employed a mouse model of the metabolic syndrome, namely Ldlr-/- mice fed a chow,
a HFHC diet, or a HFHC diet supplemented with 0.3% nobiletin (w/w) for ten weeks.
Body weight rapidly increased in mice fed the HFHC diet, which was prevented with the
supplementation of nobiletin to the same diet (Figure 2.1A). The prevention of HFHCinduced weight gain was independent of caloric intake (Figure 2.1B&C).

2.3.2

Nobiletin prevents HFHC-diet induced fasting jejunal lipid
accumulation

Previously, our laboratory has shown that significant levels of triglyceride (TG) mass
remained in the intestine of HFD-fed mice following a 6 hour fast but not in mice fed the
same HFD diet supplemented with nobiletin [11]. Furthermore, the absorption of dietary
lipid did not differ between HFD-fed and HFD-plus nobiletin-fed mice [11]. To
determine a time course estimate for intestinal TG excursion, jejunal TG was quantified
from the beginning of the light cycle throughout the course of a 9-hr fast (Figure 2-2A).
The HFHC-fed mice have significantly elevated jejunal TG at the beginning of the light
cycle, which is normalized with the addition of nobiletin to the same HFHC diet. As the
fasting time increased, the amounts of jejunal TG mass in HFHC-fed mice eventually fall
to those of chow and HFHC + nobiletin levels, indicative of intestinal-TG excursion into
plasma. However, a significantly elevated TG mass remained in the jejunum of HFHCfed mice after a 6-hour fast. Jejunal TG mass following a 6-hr fast was further quantified
in another set of mice. HFHC-fed mice had a 3-fold increase in jejunal TG and a 2.5-fold
increase in jejunal cholesteryl ester (CE), which were both completely corrected by the
addition of nobiletin to the HFHC diet (Figure 2-2B&C). Neutral lipid accumulation in
jejunal sections of the small intestine of fasted mice was visualized using Oil Red O
staining. In keeping with the biochemical analysis, greater staining was observed in the
HFHC-fed mice compared to chow-fed mice. The addition of nobiletin to the HFHC diet
markedly attenuated neutral lipid staining (Figure 2-3).
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Figure 2-1 Nobiletin prevents HFHC diet-induced weight gain.
Male Ldlr-/- mice were fed a chow, HFHC, or HFHC + nobiletin diet for 10 weeks. (A)
Structure of nobiletin. (B) Body weight gain. (C) Caloric intake expressed as kcal/g body
weight/day. Values are the mean ± SEM, * indicates significant differences in body
weight between HFHC-fed and HFHC + nobiletin-fed mice by repeated measures TwoWay ANOVA with post-hoc Tukey test, P<0.05. N.S. indicates no significant difference.
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Figure 2-2 Nobiletin prevents HFHC-diet induced fasting jejunal lipid
accumulation.
Male Ldlr-/- mice were fed a chow, HFHC, or HFHC + nobiletin diet for 10 weeks. (A)
Mice were sacrificed at the beginning of the light cycle (fed state) and after 3,6, and 9
hours (n= 4/time point). In a separate experiment, mice were fasted for 6 hours (n=1214/group). (B) Jejunal TG and (C) CE determined by lipid extraction. Data represents
mean±SEM. * and different letters are statistically different by ANOVA with post-hoc
Tukey test, P<0.05. N.S. indicates no significant difference.
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Figure 2-3 Nobiletin prevents HFHC-diet induced jejunal lipid accumulation
following a 6-hour fast.
Male Ldlr-/- mice were fed a chow, HFHC, or HFHC + nobiletin diet for 10 weeks. Mice
were sacrificed following a 6 hours (n=12-14/group). Representative frozen sections (8
µm) of jejunal segments, prepared using a cryostat, stained with Oil Red O and
counterstained with hematoxylin.
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To investigate subcellular lipid pools within the enterocytes of 6-hr fasted HFHC and
HFHC + nobiletin-fed mice, ultrastructural analyses were performed using transmission
electron microscopy (TEM). In the HFHC-fed mouse, lipids were observed in various
locations of the enterocyte (Figure 2-4A). Nobiletin treatment appeared to localize lipids
to the Golgi (Figure 3B). In the HFHC-fed mouse, lipids were observed in cytoplasmic
lipid droplets (CLDs) (Figure 2-4C), endoplasmic reticulum (Figure 2-4E). Lipid storage
in CLDs and the ER appeared to be less frequent in nobiletin treated mice (Figure 2-4D).
Together, this suggests that nobiletin more efficiently secretes lipids from dietary and
endogenous sources. Finally, we observed striking differences in presence and
morphology of other organelles between HFHC- and HFHC + nobiletin-fed mice. We
observed either round and swollen mitochondria, lysosomal or autophagosomal
organelles in the HFHC-fed mouse (Figure 2-4E). Nobiletin maintained normal
mitochondrial morphology, consisting of dense cristae features. (Figure 2-4F).
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Figure 2-4 Subcellular lipid pools within the enterocytes of 6-hr fasted HFHC and
nobiletin-treated mice.
Male Ldlr-/- mice were fed a chow, HFHC, or HFHC + nobiletin diet for 10 weeks. Mice
were sacrificed following a 6 hour fast (n=1/group). Representative ultrathin sections (90
nm) of jejunal segments, prepared using an ultramicrotome, stained with lead citrate and
visualized in a Philips 420 transmission electron microscope.
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2.3.3
2.3.3.1

Intestinal insulin signaling
Nobiletin normalizes plasma insulin and plasma free fatty
acids in response to a fasting, re-feeding protocol

In the setting of insulin resistance, plasma free fatty acids (FFA) released from adipose
tissue can accumulate in peripheral tissues, propagate insulin resistance and serve as
substrates for TG synthesis and lipid storage [19, 20]. To determine if changes in insulin
sensitivity contribute to fasting intestinal lipid accumulation in HFHC-fed mice, we
assessed intestinal insulin signaling in response to a physiological release of insulin using
a fasting-re-feeding protocol. Following a 6-hour fast, half of the mice were sacrificed in
the fasted state (low plasma insulin), while the remaining half were re-fed their respective
diets for 2 hours before sacrifice to induce a physiological release of insulin. HFHC-fed
mice displayed a 4-fold increase in fasting plasma insulin, which was corrected by
nobiletin (Figure 2-5A). Fasting plasma free fatty acids were significantly reduced by
nobiletin compared to HFHC-fed mice (Figure 2-5B). All three groups displayed a
significant reduction in plasma free fatty acids in response to re-feeding, however,
HFHC-fed mice failed to fully suppress lipolysis compared to both HFHC + nobiletin-fed
and chow-fed mice (Figure 2-55B).

59

Figure 2-5 Nobiletin reduces fasting hyperinsulinemia and restores suppression of
triglyceride lipolysis.
Male Ldlr-/- mice were fed a chow, HFHC, or HFHC + nobiletin diet for 10 weeks. Mice
were fasted for 6 hours and either sacrificed (Fast) or refed their normal diets for 2 hours
prior to sacrifice (Refed). Plasma (A) insulin and (B) free fatty acids (n=7-8/group).
Values are the mean ± SEM. Different letters indicate difference between diets in the
fasted (uppercase) and re-fed state (lowercase) between diet groups by ANOVA with
post-hoc Tukey test, P<0.05. * indicate significant differences between fasted and refed
mice within the same diet group by unpaired t-test, P<0.05.
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2.3.3.2

Nobiletin improves intestinal insulin signaling

To determine if the hyperinsulinemia and elevated plasma FFA detected in HFHC-fed
mice propagated insulin resistance to the intestine, we measured phosphorylation of
insulin signaling molecules in jejunal lysates of 6-hour fasted mice and 6-hour fasted and
2-hour re-fed mice as a measure of intestinal insulin sensitivity. In response to re-feeding,
Akt phosphorylation increased in all three groups (Figure 2-6). FoxO1 phosphorylation
was not significantly different at fasting between diet groups. In response to re-feeding,
FoxO1 phosphorylation failed to increase in the HFHC-fed mice, indicating insulin
resistance. Nobiletin significantly increased FoxO1 phosphorylation in response to refeeding (Figure 2-7). The fasting hyperinsulinemia displayed in HFHC-fed mice
appeared to be drive a small, but not significant, trend for increase in fasting mTORC1
phosphorylation, which increased further, but not significantly, in response to re-feeding
(Figure 2-8). The correction of fasting plasma insulin by nobiletin caused a small, but not
significant reduction in fasting and re-fed mTORC1 phosphorylation (Figure 2-8). We
measured the expression of the downstream effector of mTORC1 phosphorylation,
namely Srebf1c, the master regulator of de novo lipogenesis. Despite the non-significant
changes in mTORC1 phosphorylation, Srebf1c expression in HFHC-fed mice was
significantly increased in the fasted state and increased even further following re-feeding.
Nobiletin corrected Srebf1c expression in the fasted state and significantly attenuated its
increased expression in the re-fed state, compared to HFHC alone (Figure 2-9A).
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Figure 2-6 Nobiletin corrects dysregulated intestinal insulin signaling.
Male Ldlr-/- mice were fed a chow, HFHC, or HFHC + nobiletin diet for 10 weeks. Mice
were fasted for 6 hours and either sacrificed (Fast) or refed their normal diets for 2 hours
prior to sacrifice (Refed). Markers of intestinal insulin signaling were determined by
immunoblotting jejunal lysates. (A) Ratio of phosphorylated Akt to total Akt protein
(n=6-8/group) and (B) Representative gel image. Values are the mean ± SEM. Different
letters indicate difference between diets in the fasted (uppercase) and re-fed state
(lowercase) between diet groups by ANOVA with post-hoc Tukey test, P<0.05. *
indicate significant differences between fasted and refed mice within the same diet group
by unpaired t-test, P<0.05.
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Figure 2-7 Nobiletin corrects dysregulated intestinal insulin signaling.
Male Ldlr-/- mice were fed a chow, HFHC, or HFHC + nobiletin diet for 10 weeks. Mice
were fasted for 6 hours and either sacrificed (Fast) or refed their normal diets for 2 hours
prior to sacrifice (Refed). Markers of intestinal insulin signaling were determined by
immunoblotting jejunal lysates. (A) Ratio of phosphorylated FoxO1 to total FoxO1
protein (n=6-8/group) and (B) Representative gel image. Values are the mean ± SEM.
Different letters indicate difference between diets in the fasted (uppercase) and re-fed
state (lowercase) between diet groups by ANOVA with post-hoc Tukey test, P<0.05. *
indicate significant differences between fasted and refed mice within the same diet group
by unpaired t-test, P<0.05.

65

A

pFoxO1/FoxO1 Density (AU)

FoxO1
6
**** b

5
4
3
a

2

a

1
0

Fast
Refed
Chow

Fast
Refed
HFHC

Fast
Refed
HFHC + Nob

HFHC
F

HFHC+NOB HFHC+NOB
F
RF

B

Chow
F

Chow
RF

HFHC
RF

pFoxO1

82 kDa

FoxO1

80 kDa

66

Figure 2-8 Nobiletin corrects dysregulated intestinal insulin signaling.
Male Ldlr-/- mice were fed a chow, HFHC, or HFHC + nobiletin diet for 10 weeks. Mice
were fasted for 6 hours and either sacrificed (Fast) or refed their normal diets for 2 hours
prior to sacrifice (Refed). Markers of intestinal insulin signaling were determined by
immunoblotting jejunal lysates. (A) Ratio of phosphorylated mTORC1 to total mTORC1
protein (n=6-8/group) and (B) Representative gel image. Values are the mean ± SEM.
Different letters indicate difference between diets in the fasted (uppercase) and re-fed
state (lowercase) between diet groups by ANOVA with post-hoc Tukey test, P<0.05. *
indicate significant differences between fasted and refed mice within the same diet group
by unpaired t-test, P<0.05.
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Figure 2-9 Nobiletin corrects dysregulated intestinal insulin signaling.
Male Ldlr-/- mice were fed a chow, HFHC, or HFHC + nobiletin diet for 10 weeks. Mice
were fasted for 6 hours and either sacrificed (Fast) or refed their normal diets for 2 hours
prior to sacrifice (Refed). Markers of intestinal insulin signaling were determined by
immunoblotting of jejunal lysates. (A) Expression of jejunal Srebf1c relative to Gapdh,
determined by qRT-PCR (n=6-8/group). Values are the mean ± SEM. Different letters
indicate difference between diets in the fasted (uppercase) and re-fed state (lowercase)
between diet groups by ANOVA with post-hoc Tukey test, P<0.05. * indicates
significant differences between fasted and refed mice within the same diet group by
unpaired t-test, P<0.05.

69

A

Srebf1c
****

Srebf1c/Gapdh

8

b

6

***

c

4
B

2
0

A

a

Fast Refed
Chow

A
Fast Refed
HFHC

Fast Refed
HFHC + Nob

70

2.3.4

Nobiletin corrects intestinal de novo lipogenesis

To determine if the aberrant intestinal insulin signaling and elevated plasma FFA
detected in HFHC-fed mice increases fasting de novo lipogenesis, we measured de novo
lipogenesis within the jejunum of 6 hour fasted mice ex vivo. HFHC-fed mice had
increased jejunal fatty acid synthesis (Figure 2-10A) and triglyceride synthesis (Figure 210B), both of which were corrected by nobiletin. Despite marked improvements in
intestinal mitochondrial morphology observed by TEM (Figure 2-4E&F), the capacity for
jejunal fatty acid oxidation was significantly increased in mice fed the HFHC alone and
only a trend for further increase was observed with nobiletin treatment (Figure 2-10C).
This equivalent potential to oxidize fat suggests that the reduced fasting intestinal lipid
accumulation in nobiletin-treated mice is not due to an increased capacity for fatty acid
oxidation.
Collectively, these results indicate that addition of nobiletin to the HFHC diet prevents
the induction of Srebf1c expression resulting in attenuated intestinal de novo fatty acid
synthesis thereby limiting excess TG substrate for intestinal lipid storage. However, other
mechanisms including altered dynamics of TG storage and subsequent excursion of
dietary fat into could also be involved.
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Figure 2-10 Nobiletin prevents fasting de novo lipogenesis.
Male Ldlr-/- mice were fed a chow, HFHC, or HFHC + nobiletin diet for 10 weeks. (A)
Jejunal fatty acid synthesis was determined by injecting 14C-acetic acid (i.p.) following a
6 hour fast and killing the mice 1 hour later. 14C-acetic acid incorporation into fatty acids
from jejunal lipid extracts following saponification (n=7-8/group). (B) Jejunal
triglyceride synthesis was determined by 14C-oleate incorporation ex vivo (n=7/group).
(C) Jejunal fatty acid oxidation was determined by 14C-Palmitate conversion to 14CO2 in
mucosal scrapings (n=14-15/group). Values are the mean ± SEM, different letters are
statistically different by ANOVA with post-hoc Tukey test, P<0.05.
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2.3.5
2.3.5.1

Postprandial intestinal glucose metabolism
Nobiletin prevents HFHC-diet induced hyperinsulinemia in
response to a glucose challenge

Previously, our lab reported that an intraperitoneal (i.p.) glucose tolerance test (GTT) in
nobiletin treated HFHC-fed Ldlr-/- mice revealed improved glucose tolerance, indicative
of improved whole body insulin sensitivity [13]. However, this route of glucose
administration excludes the incretin response that is known to potentiate glucosestimulated insulin secretion [7, 21]. Therefore, we further explored the HFHC dietinduced dysregulation of hormonal signaling within the gut on glucose metabolism and
the potential correction by nobiletin.
Following a 6-hour fast, we challenged the mice with a glucose load delivered either i.p.,
which bypasses the intestine and thus prevents incretin release, or by oral gavage.
Nobiletin improved the impaired glucose tolerance observed in HFHC-fed mice
following a glucose load administered i.p. (Figure 2-11A) and by oral-gavage (Figure 211B). The glucose challenge delivered i.p. caused a 60-fold increase in plasma insulin in
HFHC mice after 15 minutes, which was decreased after 30 minutes, but remained high
throughout the course of the experiment (Figure 2-12A). HFHC + nobiletin-fed mice
exhibited less than a 20-fold increase in plasma insulin compared to chow after 15
minutes, which returned to baseline by the end of the experiment (Figure 2-12A).
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Figure 2-11 Nobiletin improves oral glucose tolerance.
Male Ldlr-/- mice were fed a chow, HFHC, or HFHC + nobiletin diet for 10 weeks. Mice
were fasted for 6 hours and blood was sampled before and every 15 minutes after a
glucose load for blood glucose and plasma insulin measurements. Half of the mice
received an intraperitoneal glucose tolerance test (IPGTT) and the other half received the
glucose challenge by oral gavage (OGTT) (1g/kg body weight). Blood glucose was
measured by glucometer. (A) IPGTT and (B) OGTT. Glucose utilization was determined
as the area under the curve (AUC). Values are the mean AUC ± SEM. Different letters
are statistically different groups by ANOVA with post-hoc Tukey test, P<0.05.

75

(i.p.) GTT

2500

15

1500

10

1000

5

500

0

0

30

Time
(min)
60

90

i.p. AUC

2000
AUC

Chow
HFHC
HFHC + Nob

20

[Glucose] (mmol/L)

Blood glucose (mmol/L)

A

0

120

Time (min)

Oral GTT
2000

20
15

AUC

Blood glucose (mmol/L)

B

10
5
0

1500
1000
500

0

30

60

Time (min)

90

120

0

Oral AUC
b
a
a

76

When the glucose load was administered orally, the HFHC displayed a 200-fold increase
in plasma insulin, which was completely normalized by nobiletin (Figure 2-12B). The
hyperinsulinemia displayed by the HFHC mice in both GTTs was significantly elevated
compared to chow and HFHC + nobiletin as assed by the areas under the plasma insulin
curves (Figure 2-12C). Calculation of the plasma glucose to insulin ratio at 15 minutes
following both GTTs revealed more insulin was secreted following the oral GTT for the
same increase in blood glucose (Figure 2-12D). However, HFHC-fed mice secrete
significantly more insulin per mmol/L of blood glucose 15 minutes after the glucose
challenge, especially following oral glucose challenge (Figure 2-12D). This demonstrated
the incretin effect following oral glucose administration and suggests that HFHC-fed
mice, but not nobiletin-treated mice, had significantly larger insulin storage within islets.
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Figure 2-12 Nobiletin prevents hyperinsulinemia during a glucose challenge.
Male Ldlr-/- mice were fed a chow, HFHC, or HFHC + nobiletin diet for 10 weeks. Mice
were fasted for 6 hours and blood was sampled before and every 15 minutes after a
glucose load for blood glucose and plasma insulin measurements. Half of the mice
received an intraperitoneal glucose tolerance test (IPGTT) and the other half received the
glucose challenge by oral gavage (OGTT) (1g/kg body weight). Plasma insulin was
measured by enzyme-linked immunosorbent assay. (A) Plasma insulin throughout the
course of the IPGTT and (B) the OGTT. (C) Plasma insulin secretion determined as the
AUC. (D) Glucose:insulin ratio 15 minutes post-glucose load. Values are the mean ±
SEM. Statistical difference between groups for the IPGTT are indicated by different
uppercase letters and differences between groups for the OGTT are indicated by
lowercase letters by ANOVA with post-hoc Tukey test, P<0.05.
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2.3.5.2

Plasma incretin levels in response to an oral glucose
challenge

GLP-1 and GIP are secreted from intestinal L-cells and K-cells, respectively, in response
to nutrients [7]. Furthermore, they potentiate glucose-stimulated insulin secretion and are
both subject to degradation by DPP4 [7]. We measured fasting DPP4 as well as fasting
and post-oral gavage of glucose (at 15 min.) plasma insulin, GLP-1 and GIP to determine
if the prevention of hyperinsulinemia by nobiletin was related to changes in incretin
release (Figure 2-13&2-14). Fasting plasma DPP4 activity was significantly increased in
HFHC-fed mice and in HFHC + nobiletin-fed mice (Figure 2-13A). Fasting plasma GLP1 in HFHC-fed mice were at the same concentration as that in chow-fed mice (Figure 213B). In nobiletin treated mice, however, fasting plasma GLP-1 was significantly
increased (Figure 2-13B). There was no observable change in plasma GLP-1 15 minutes
after the oral glucose challenge in any of the diet groups (Figure 2-13B). The
hyperinsulinemia observed at fasting and 15 minutes after the oral glucose challenge in
HFHC-fed mice was associated with increased levels of fasting and post-glucose gavage
plasma GIP (Figure 2-14). Nobiletin normalized fasting and post-gavage plasma GIP
(Figure 2-14). Collectively, these results demonstrated the influence of HFHC-feeding on
the incretin response to glucose. The increased plasma GLP-1, but not GIP levels, in
nobiletin-treated mice compared to chow and HFHC was surprising considering the
elevated fasting DPP4 activity, suggesting that endogenous GLP-1 secretion is a potential
molecular target of nobiletin.
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Figure 2-13 Plasma incretin levels following an oral glucose challenge.
Male Ldlr-/- mice were fed a chow, HFHC, or HFHC + nobiletin diet for 10 weeks. Mice
were fasted for 6 hours and blood was sampled before and at 15 minutes after an oral
glucose challenge (1g/kg body weight). DPP4 activity was determined by fluorometric
assay. Plasma insulin was measured by enzyme-linked immunosorbent assay. Active
plasma GLP-1 was measured by Mesoscale. (A) Fasting plasma DPP4 activity. Fasting
(0) and 15 min (15) post-OGTT (B) plasma insulin and (C) GLP-1 measurements. Values
are the mean ± SEM. Statistical difference between groups at fasting are indicated by
different uppercase letters, differences between groups 15 min post-gavage are indicated
by different lowercase letters and differences between the delta (15min-0hr) from
baseline in each group are indicated by different symbols by ANOVA with post-hoc
Tukey test, P<0.05.
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Figure 2-14 Plasma GIP levels following an oral glucose challenge.
Male Ldlr-/- mice were fed a chow, HFHC, or HFHC + nobiletin diet for 10 weeks. Mice
were fasted for 6 hours and blood was sampled before and at 15 minutes after an oral
glucose challenge (1g/kg body weight). Active plasma GIP was measured by Mesoscale.
(A) Fasting (0) and 15 min (15) post-OGTT plasma GIP measurements. Values are the
mean ± SEM. Statistical difference between groups at fasting are indicated by different
uppercase letters, differences between groups 15 min post-gavage are indicated by
different lowercase letters and differences between the delta (15min-0hr) from baseline in
each group are indicated by different symbols by ANOVA with post-hoc Tukey test,
P<0.05.
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2.3.5.3

Nobiletin prevents HFHC-diet induced increase in β-cell
mass

Previous studies have determined that prolonged high-fat feeding induces β-cell
proliferation and increased β-cell mass [22]. Interestingly, β-cell proliferation has been
shown to occur as early as three days following high-fat feeding and therefore prior to
insulin resistance [22]. To determine if the prevention of HFHC-diet induced
hyperinsulinemia by nobiletin was due to a change in stored insulin, we quantified β-cell
mass and the number of islets in pancreata of 6 hour-fasted mice. HFHC-feeding
increased the size of insulin-positive islets (Figure 2-15 representative pictures).
Nobiletin significantly reduced β-cell mass compared to HFHC-fed mice (Figure 2-16)
while islet number and pancreas weight did not significantly differ between diet groups
(Figure 2-16B&C).
Collectively, these results indicated that addition of nobiletin to the HFHC diet prevented
β-cell mass expansion and aberrant GIP responses to oral glucose resulting in a an
attenuation of fasting and postprandial hyperinsulinemia. Moreover, they provide further
evidence that intestinal hormones contribute to metabolic dysregulation in HFHC-fed
mice and suggested that GIP may be a potential molecular target of nobiletin within the
gut.
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Figure 2-15 Nobiletin prevents HFHC-diet induced β-cell mass expansion.
Male Ldlr-/- mice were fed a chow, HFHC, or HFHC + nobiletin diet for 10 weeks. Mice
were sacrificed following a 6 hour fast. (A) Representative paraffin sections (5 µm) of
pancreas, prepared using a microtome, immunostained for insulin and counterstained
with hematoxylin (Scale bar = 3 mm). (B) Representative photomicrographs of insets
(Scale bar = 500 um).

HFHC + Nob

HFHC

Chow

86

A
B

87

Figure 2-16 Nobiletin prevents HFHC-diet induced β-cell mass expansion.
Male Ldlr-/- mice were fed a chow, HFHC, or HFHC + nobiletin diet for 10 weeks. Mice
were sacrificed following a 6 hour fast. Islet number and size were quantified using a
light microscope slide scanner counting all islets within 3 sections/mouse >150 µm apart.
β-cell mass was calculated by β-cell area/non-islet area x pancreas weight (n=4-6/group).
(A) β-cell mass. (B) Estimate of the total number of insulin-expressing islets per
pancreas. (C) Pancreas weight. Values are the mean ± SEM, different letters are
statistically different by ANOVA with post-hoc Tukey test, P<0.05.
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2.3.6
2.3.6.1

Postprandial intestinal lipid metabolism
Nobiletin prevents intestinal lipid accumulation following an
oral-fat gavage

Recent studies highlight that newly synthesized TG is not immediately secreted out of the
enterocyte; rather, a considerable amount is stored in cytoplasmic lipid droplets (CLDs)
as an overflow reservoir for later export [3]. Moreover, high-fat fed mice have been
reported to have considerably more frequent and larger intestinal CLDs following an oral
fat challenge compared to low fat-fed controls [23, 24]. To determine if HFHC +
nobiletin feeding alters postprandial intestinal TG handling, we challenged mice to an
oral gavage of olive oil (Figure 2-17A).
Neutral lipid accumulation in jejunal sections of the small intestine of mice 2-hrs after the
olive oil gavage was visualized using paraphenylendiamine staining. Punctate staining
was observed in the intracellular space of HFHC-fed mice, however, the addition of
nobiletin to the HFHC diet markedly attenuated neutral lipid staining (Figure 2-17). TEM
was used to investigate subcellular lipid pools within the enterocytes of mice 2-hrs after
the olive oil gavage. The olive oil gavage induced a striking formation of numerous large
CLDs in all of the enterocytes of the HFHC-fed mouse (Figure 2-18A,C,E). By contrast,
large CLDs were far less frequent with nobiletin treatment (Figure 2-18B). Rather, we
observed smaller CLDs, likely associated with ER organelles with nobiletin treatment
(Figure 2-18B,D,F). Similar to the fasted state, we observed round mitochondria in the
HFHC-fed 2-hrs after the olive oil gavage, while long mitochondrial ultrastructures were
observed with nobiletin treatment at this time point (Figure 2-18A&B). Chylomicrons
were observed in the extracellular space, likely travelling towards the basolateral side of
the enterocyte in mice fed the HFHC and the HFHC supplemented with nobiletin (Figure
2-18C&D). Unlike the HFHC-fed mouse, we observed lipid-loaded ER ultrastructures
with nobiletin treatment, indicative of accelerated chylomicron assembly (Figure 2-18B).

90

Figure 2-17. Postprandial jejunal accumulation.
Male Ldlr-/- mice were fed a chow, HFHC, or HFHC + nobiletin diet for 10 weeks. Mice
were fasted for 6 hours, administered an olive oil gavage and sacrificed 2 hours later. (A)
Experimental design. (B) Representative semi-thin sections (0.5 µm) of jejunal segments,
prepared using an ultramicrotome, stained with paraphenylenediamine. Arrows indicate
punctate staining of neutral lipid droplets.
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Figure 2-18 Nobiletin reduces HFHC-diet induced CLD formation.
Male Ldlr-/- mice were fed a chow, HFHC, or HFHC + nobiletin diet for 10 weeks. Mice
were fasted for 6 hours, administered an olive oil gavage and sacrificed 2 hours later
(n=1/group). Representative ultrathin sections (90 nm) of jejunal segments, prepared
using an ultramicrotome, stained with lead citrate and visualized in a Philips 420
transmission electron microscope.
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Additionally, we observed secretory vesicles only in the HFHC+nobiletin-fed mouse,
once again highlighting the efficiency of lipid packaging for excursion from enterocytes
at this time point.
We also quantified TG mass throughout the entire length of the small intestine 2 hours
and 4 hours following the oral-fat load containing both cold olive oil and 3H-triolein.
Distribution of radiolabeled lipids from the olive oil gavage throughout the small
intestine at 2 hours showed no significant difference in area under the curves between
diet groups, indicative that there was no difference in absorption (Figure 2-19). There
was, however, a non-significant trend for an increase in 3H-lipids, corresponding to
gavage (lumenal) TG only, in the proximal intestine in HFHC-fed mice compared to
chow-fed and nobiletin-treated mice whose 3H-lipid peaks were mid-jejunum (Figure 219). HFHC-fed mice had elevated TG mass, corresponding to gavage TG as well as TG
stored in lipid droplets, throughout the small intestine 2-hrs after the olive oil gavage,
which was normalized with nobiletin treatment (Figure 2-20A). This reduced triglyceride
area under the curve with nobiletin treatment was significant in the sections
corresponding to the jejunum (Figure 2-20C). HFHC-fed mice had elevated TG mass
throughout the small intestine 4-hrs after the olive oil gavage, however, reduced TG area
under the curve with nobiletin treatment was not significant (Figure 2-21).

95

Figure 2-19 Distribution of radiolabeled lipids from the olive oil gavage throughout
the small intestine.
Male Ldlr-/- mice were fed a chow, HFHC, or HFHC + nobiletin diet for 10 weeks. Mice
were fasted (6 hours) and received oral gavage of 200 µL of olive oil containing
[3H]triolein. Half of the mice were sacrificed at 2 hours and the other half at 4 hours postgavage (n=8/group/time). Whole intestine was excised and the small intestine divided
into 12 equal segments for lipid extractions. (A) Distribution of radioactive tracer uptake
along the small intestine axis from pylorus (proximal) to the ileocecal junction (distal) 2hours post-gavage and area under the curve (AUC) calculations. Values are the mean ±
SEM, different letters are statistically different, by ANOVA with post-hoc Tukey test,
P<0.05. N.S. indicates no significant difference.
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Figure 2-20 Postprandial intestinal lipid metabolism.
Male Ldlr-/- mice were fed a chow, HFHC, or HFHC + nobiletin diet for 10 weeks. Mice
were fasted (6 hours) and received oral gavage of 200 µL of olive oil containing
[3H]triolein. Half of the mice were sacrificed at 2 hours and the other half at 4 hours postgavage (n=8/group/time). Whole intestine was excised and the small intestine divided
into 12 equal segments for lipid extractions. (A) TG concentration along the small
intestine axis from pylorus (proximal) to the ileocecal junction (distal) 2-hours postgavage and area under the curve (AUC) calculations of (B) the entire small intestine and
(C) the jejunal segments. Values are the mean ± SEM, different letters are statistically
different, by ANOVA with post-hoc Tukey test, P<0.05. N.S. indicates no significant
difference.
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Figure 2-21 Postprandial intestinal lipid metabolism.
Male Ldlr-/- mice were fed a chow, HFHC, or HFHC + nobiletin diet for 10 weeks. Mice
were fasted (6 hours) and received oral gavage of 200 µL of olive oil containing
[3H]triolein. Half of the mice were sacrificed at 2 hours and the other half at 4 hours postgavage (n=8/group/time). Whole intestine was excised and the small intestine divided
into 12 equal segments for lipid extractions. (A) TG concentration along the small
intestine axis from pylorus (proximal) to the ileocecal junction (distal) 4-hours postgavage and area under the curve (AUC) calculations of (B) the entire small intestine and
(C) the jejunal segments. Values are the mean ± SEM, different letters are statistically
different, by ANOVA with post-hoc Tukey test, P<0.05. N.S. indicates no significant
difference.
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2.3.6.2

Postprandial triglyceridemic response

To determine if the decrease in postprandial intestinal TG accumulation is due to an
increased excursion of lipid out of the intestine, we measured plasma triglyceride
concentration every 2 hours for up to 8 hours following the same olive oil gavage.
HFHC-fed mice are hyperlipidemic following a 6 hour fast, which is corrected by
nobiletin (Figure 2-22A). In all three-diet groups, plasma triglyceride peaks at 2 hours
post-gavage and returns to baseline by the 8-hour time point (Figure 2-22A). Similarly,
fast protein liquid chromatography (FPLC) fractionation of fasting (6 hr) plasma TGs
revealed a significant increase in the plasma VLDL fraction of HFHC-fed mice, which
was significantly attenuated with nobiletin treatment (Figure 2-22-B). Interestingly, 2
hours following the olive oil gavage, the TG AUC of the VLDL/chylomicron fraction of
HFHC did not significantly increase from baseline, suggesting delayed intestinal-TG
excursion (Figure 2-22D). By contrast, the TG AUC of the VLDL/chylomicron fraction
of nobiletin-treated mice significantly increased from baseline (Figure 2-22D), suggesting
increased intestinal-TG excursion.
In mice following an olive oil gavage, the secretion of TG into plasma from the intestine
is primarily in chylomicrons and VLDL-sized particles. In another set of mice, we
isolated the plasma chylomicron fraction and the VLDL fraction separately by
ultracentrifugation. In the chylomicron fraction, triglyceride concentration peaked at 2
hours following the olive oil gavage in HFHC-fed mice (Figure 2-23A). The
chylomicron-triglyceride peak in nobiletin treated mice, however, occurred at the 1-hour
time-point (Figure 2-23A). In the VLDL fraction, which is largely intestinally derived,
triglycerides peaked once again 2-hours following the oral fat load in HFHC-fed mice,
whereas this peak appeared at the 1-hour time point in nobiletin treated mice (Figure
23B). The shift in triglyceride peak in both chylomicrons and VLDL from 2-hours to 1hour post-gavage and reduced triglyceride AUC with nobiletin treatment suggests
enhanced secretion of intestinally derived triglyceride occurs within the first hour and is
followed by enhanced clearance from plasma.
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Figure 2-22 Postprandial plasma triglyceride response.

Male Ldlr-/- mice were fed a chow, HFHC, or HFHC + nobiletin diet for 10 weeks. (A)
Plasma triglyceride concentration at baseline (6 hour fast) and at 2, 4, 6 and 8 hours after
an olive oil gavage. In another set of mice, plasma was collected following a 6 hour fast
and at 2 hours after mice were challenged with an oral gavage of olive oil. Plasma was
subjected to fast protein liquid chromatography (FLPC) and triglycerides were measured
in each fraction by enzymatic assay (n=8-12/group). (B) Fasting plasma triglycerides. (C)
Plasma triglycerides 2 hours post olive oil gavage. (D) Fasting and post gavage plasma
VLDL triglyceride AUC calculations and absolute change from baseline (Δ). Values are
the mean ± SEM. * indicates statistical significance between HFHC-fed mice and HFHC
+ nobiletin-fed mice by repeated measures Two-Way Anova with post-hoc Tukey test,
P<0.05. Statistical difference between groups at fasting are indicated by different
uppercase letters, differences between groups 15 min post-gavage are indicated by
different lowercase letters and differences between the delta (15min-0hr) from baseline in
each group are indicated by different symbols by ANOVA with post-hoc Tukey test,
P<0.05.
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Figure 2-23 Postprandial plasma triglyceride response.
Male Ldlr-/- mice were fed a chow, HFHC, or HFHC + nobiletin diet for 10 weeks. (A)
Plasma triglyceride concentration at baseline (6 hour fast) and at 2, 4, 6 and 8 hours after
an olive oil gavage. In another set of mice, plasma was subjected to ultracentrifugation to
isolate the (A) Chylomicron fraction and the (B) VLDL fraction triglyceride
concentration at baseline (6 hour fast) and at 1, 2 and 4 hours after an olive oil gavage. *
indicates statistical significance between HFHC-fed mice and HFHC + nobiletin-fed mice
by repeated measures Two-Way Anova with post-hoc Tukey test, P<0.05.
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2.3.6.3

Nobiletin increases intestinal-TG secretion following an
oral-fat gavage

To directly determine intestinal-TG secretion rates, plasma was collected from 6-hour
fasted mice following an injection of poloxamer-407, an inhibitor of lipoprotein
catabolism, and challenged with an oral gavage of 3H-triolein in olive oil (Figure 2-24A).
Plasma triglycerides were plotted as a change from baseline (6-hr fast). HFHC-fed mice
displayed a delayed appearance of TG mass in the plasma, which was significantly
corrected with nobiletin treatment (Figure 2-24B). The appearance of 3H-TG into to
plasma was also significantly delayed, particularly 2 hours post-gavage in HFHC-fed
mice, whereas the rate of appearance of 3H-TG in plasma was also significantly
increased with nobiletin treatment (Figure 2-24B). Despite the delayed dietary TG
secretion in the HFHC-fed mice, there was no significant change in plasma apoB48
secretion between HFHC + nobiletin and HFHC alone(Figure 2-25). Although mice
produce apoB48 as a scaffold for both intestinal and liver lipoprotein formation, the
plasma apoB48 signal measured post-olive oil gavage was likely dominated by the
intestinal contribution.
To determine if nobiletin alters TG secretion from the intestine compared mice fed the
HFHC-diet alone, we measured plasma, chylomicron fraction and VLDL fraction TG
before and at 2 hours following an olive oil gavage in mice treated with poloxamer-407.
As previously shown by others [23, 25], HFHC-fed mice displayed a significantly lower
TG secretion into plasma 2 hours after the olive oil gavage (Figure 2-26A). Nobiletin
significantly increased plasma TG secretion at this time point (Figure 2-26A). HFHC-fed
mice also displayed a delayed TG secretion in the chylomicron fraction and in the VLDL
fraction of plasma (Figure 2-26 B&C). Nobiletin significantly increased TG secretion in
both fractions (Figure 2-26 B&C). We did not detect a difference in apoB48 secretion at
2 hours in the chylomicron fraction between diet groups (Figure 2-26D), indicating that
nobiletin loaded more TG onto each apoB48 particle in the chylomicron fraction
compared to HFHC alone. However, a significantly decreased apoB48 secretion at 2
hours was observed in the VLDL fraction in HFHC-fed mice, which was attenuated by
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nobiletin (Figure 2-26 E). This suggests that nobiletin increased the number of apoB48
particles into the VLDL fraction.
When comparing the ratio of apB48 to TG mass within each fraction, as a surrogate for
measuring particle size, a trend for increase was observed in the HFHC-fed mice in the
chylomicron fraction, suggesting a decrease in TG content per lipoprotein particle at 2
hours (Figure 2-27A). This trend for decrease was reversed with nobiletin treatment
(Figure 2-27A). In the VLDL fraction, the opposite trend was observed: HFHC-fed mice
appeared to increase their TG content per lipoprotein particle (likely intestinally derived)
at 2 hours (Figure 2-27B). Together, this suggests that nobiletin enhances intestinal TG
secretion by increasing TG content in the chylomicron fraction as well as increasing the
number of particles in the VLDL fraction.

108

Figure 2-24 Postprandial plasma triglyceride response.
Male Ldlr-/- mice were fed a chow, HFHC, or HFHC + nobiletin diet for 10 weeks. Mice
were fasted (6 hours) and administered poloxamer-407 (i.p.), and 30 minutes later
received an oral gavage of 200 µL of olive oil containing [3H]triolein. Half of the mice
were sacrificed at 2 hours and the other half at 4 hours post-gavage. Plasma was collected
from mice following a 6 hour fast and 1, 2, and 4 hours post-gavage for (A) Plasma
triglyceride mass and (B) Plasma [3H]triglyceride expressed as a difference from
baseline and the area under the curve (AUC) calculations. Values are the mean ± SEM,
different letters are statistically different, by ANOVA with post-hoc Tukey test, P<0.05.
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Figure 2-25 Postprandial plasma triglyceride response.
Male Ldlr-/- mice were fed a chow, HFHC, or HFHC + nobiletin diet for 10 weeks. Mice
were fasted (6 hours) and administered poloxamer-407 (i.p.), and 30 minutes later
received oral gavage of 200 µL of olive oil containing [3H]triolein. Half of the mice were
sacrificed at 2 hours and the other half at 4 hours post-gavage. Plasma was collected from
mice following a 6 hour fast and 1, 2, and 4 hours post-gavage for (A) Plasma apoB48
signal determined by immunoblot and expressed as a difference from baseline and area
under the curve (AUC) calculations. A representative immunoblot of apoB48 is shown
below. Values are the mean ± SEM, different letters are statistically different, by
ANOVA with post-hoc Tukey test, P<0.05.
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Figure 2-26 Nobiletin enhances intestinally derived triglyceride secretion following
an oral fat load.
Male Ldlr-/- mice were fed a chow, HFHC, or HFHC + nobiletin diet for 10 weeks. (A)
Plasma triglyceride concentration at baseline (6 hour fast) and at 2 hours after an olive oil
gavage. Plasma was ultracentrifuged to isolate the (B) chylomicron fraction and the (C)
VLDL fraction triglyceride concentration at baseline (6 hour fast) and at 2 hours after the
olive oil gavage. ApoB48 levels were measured by immunoblot and normalized to
albumin in the (D) chylomicron and (E) VLDL fraction. A representative immunoblot of
apoB48 is shown below. Values are the mean ± SEM. Statistical difference between
groups at fasting are indicated by different uppercase letters, differences between groups
2 hours post-gavage are indicated by different lowercase letters and differences between
the delta (2hr-0hr) from baseline in each group are indicated by different symbols by
ANOVA with post-hoc Tukey test, P<0.05.
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Figure 2-27 Estimate of lipoprotein particle size.
Male Ldlr-/- mice were fed a chow, HFHC, or HFHC + nobiletin diet for 10 weeks.
ApoB48:TG ratio was calculated as a surrogate measure of particle size within the (A)
Chylomicron fraction and (B) VLDL fraction. Values are the mean ± SEM, different
letters are statistically different, P<0.05. N.S. indicates no statistical significance.

115

A

ApoB48 signal:mmol/L

Chylomicron fraction – Apo B48:TG
0.5

N.S.

0.4
0.3
0.2
0.1
0.0

B

Chow

HFHC

HFHC + Nob

ApoB48 signal:mmol/L

VLDL fraction – Apo B48:TG
0.20

N.S.

0.15
0.10
0.05
0.00

Chow

HFHC

HFHC + Nob

116

2.3.6.4

Nobiletin increases intestinal-TG clearance following an
oral-fat gavage

To establish an estimate chylomicron TG clearance rate, we compared chylomicron
fraction TG secretion rates (with poloxamer-407 treatment) to chylomicron TG changes
from baseline (without poloxamer-407 treatment) in the same set of mice 2 hours after an
olive oil gavage (Figure 2-28A). When subtracting the absolute values, we were able to
derive an estimate of the clearance rate. The HFHC-diet suppression of chylomicron TG
clearance was significantly reversed by nobiletin treatment (Figure 2-28B). Therefore, in
addition to increasing intestinal chylomicron TG secretion, nobiletin decreases
chylomicron TG retention time in the circulation.
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Figure 2-28 Estimate of intestinally-derived triglyceride clearance rate.
Male Ldlr-/- mice were fed a chow, HFHC, or HFHC + nobiletin diet for 10 weeks. (A)
Comparison of chylomicron-fraction secretion rates in mice treated with poloxamer-407
(circles) and in mice without poloxamer-407 (triangles) 2 hours after an acute dietary
challenge. (B) Estimated clearance rate. Values are the mean ± SEM, different letters are
statistically different, P<0.05.
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2.3.6.5

Nobiletin influences the expression of genes involved in
intestinal lipid metabolism

CD36, DGAT2 and MTP are involved in fatty acid trafficking, TG synthesis and TG
loading onto apoB48 for chylomicron assembly, respectively [26]. Since nobiletin
significantly reduced jejunal TG mass 2-hours post-oil gavage compared to HFHC-fed
mice and that changes in jejunal gene expression have been reported to occur at 2-hours
post-oil gavage in lean versus obese mice [25], jejunal mucosa scrapings were analyzed
for mRNA expression by qRT-PCR at this time point. There was a trend to increased
Cd36 expression in HFHC-fed mice, but not with nobiletin treatment (Figure 2-29A).
There was no change in the expression of Dgat2 between diets (Figure 2-29B).
Additionally, there was no change in Mttp expression (Figure 2-29C). As in the fasted
state, Srebf1c expression in HFHC-fed mice was significantly increased 2 hours postolive oil gavage, which was completely corrected by nobiletin (Figure 2-29D). Adipose
triglyceride lipase (ATGL) mediates the hydrolysis of triglyceride from CLDs, and its
expression has previously been shown to be reduced from baseline 2-hours following an
olive oil gavage in high-fat fed mice [27]. The addition of nobiletin to the HFHC diet
significantly increased Atgl mRNA abundance compared to that of HFHC-fed mice,
which may increase substrate for chylomicron synthesis rather than storage (Figure 229E). Plin2 is involved in CLD stabilization and hydrolysis; there was a non-significant
trend for increase in its expression with nobiletin compared to HFHC-fed mice.

Collectively, these results indicate that addition of nobiletin to the HFHC diet prevents
intestinal triglyceride accumulation, in part, by preventing HFHC-diet induced increase in
postprandial Srebf1c expression, thereby limiting non-dietary TG substrate for intestinal
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lipoprotein formation. Furthermore, the increased expression of Atgl and Plin2 suggest
enhanced liberation of fatty acids stored in CLDs for either oxidation or TG re-synthesis
for chylomicron formation. As such, the jejuna of nobiletin-treated mice are more
prepared to handle an acute oral fat challenge.
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Figure 2-29 Nobiletin influences the expression of genes involved in intestinal
triglyceride metabolism.
Male Ldlr-/- mice were fed a chow, HFHC, or HFHC + nobiletin diet for 10 weeks.
Expression of (A) Cd36, (B) Dgat2, (C) Mttp, (D) Srebf1c, (E) Atgl and (F) Plin2 in
jejunal mucosa scrapings by qRT-PCR. Values are the mean ± SEM, different letters are
statistically different, P<0.05. N.S. indicates no statistical significance.
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2.3.7
2.3.7.1

Evidence for a possible mechanism involving gut hormones
Nobiletin improves physical gut parameters

It has been previously shown that chronic high-fat feeding in mice shortens the length of
the small intestine and modulates metabolic endotoxemia [28]. The HFHC diet
significantly shortened small intestinal length, which was corrected by nobiletin (Figure
2-30A). A representative image is shown in Figure 2-30C. Similarly, the HFHC-diet
suppression of small intestinal wet weight was increased by nobiletin (Figure 2-30B).
Nobiletin also increased fasting (6 hr) crypt-villus height compared to HFHC and chowfed mice (Figure 2-30D; Representative images Figure 2-30F). To determine if nobiletin's
influence on small intestinal length and weight impacted gut-barrier function, we
measured plasma lipopolysaccharide (LPS) in HFHC- and HFHC + nobiletin-fed mice
following a 6 hour fast. Nobiletin significantly reduced fasting plasma LPS (Figure 230E) suggesting improved barrier function. At this stage, it remains unknown whether the
effect of nobiletin on small intestinal length, weight and barrier function are linked to the
prevention of intestinal lipid accumulation or systemic metabolic protection by nobiletin.
Interestingly, gut hormone glucagon-like peptide 2 (GLP-2) has been shown to improve
all of these parameters and increase intestinal TG secretion.

2.3.7.2

Nobiletin increases plasma GLP-1 in response to an oral
fat challenge

As previously mentioned, GLP-1 lowers glycemia and post-prandial plasma chylomicron
triglycerides in response to a meal [7]. In the present study, a significant increase in
fasting plasma GLP-1 concentrations were observed in nobiletin treated mice (Figure 231). In response to an acute dietary fat challenge, plasma GLP-1 levels were increased
after 10 minutes in all three diet groups, where absolute plasma GLP-1 levels at 10
minutes were significantly increased with nobiletin treatment, compared to HFHC alone
and chow-fed mice (Figure 2-31). Reliable assays for plasma GLP-2 in mice are not
currently available [7]. However, as GLP-1 and GLP-2 are products of the same gene, it
is most likely that the nobiletin-induced increase in plasma GLP-1 was accompanied by
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Figure 2-30 Nobiletin improves physical gut parameters.
Male Ldlr-/- mice were fed a chow, HFHC, or HFHC + nobiletin diet for 10 weeks. Mice
were fasted for 6 hours and whole intestines were removed for (A) Small intestinal length
(B) small intestinal weight measurements as well as (C) representative photomicrographs
of small intestinal sections. Fasting crypt-villus height was measured in frozen sections (8
µm) of jejunal segments, prepared using a cryostat, stained with Oil Red O and
counterstained with hematoxylin. (F) Representative photomicrographs. (D) Fasting (6
hour) plasma lipopolysaccharide in HFHC and HFHC+nobiletin fed mice determined by
colorimetric assay. Values are the mean ± SEM, different letters are statistically different,
P<0.05.
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increased GLP-2. As the plasma half-life of GLP-2 is 7-fold longer than that of GLP-1, it
is assumed that the metabolic effects of endogenous GLP-2 predominate over those of
endogenous GLP-1 [7]. Nevertheless, these data suggest that nobiletin may increase
endogenous gut hormone levels including GLP-1 and GLP-2.

127

Figure 2-31 Nobiletin increases plasma GLP-1.
Male Ldlr-/- mice were fed a chow, HFHC, or HFHC + nobiletin diet for 10 weeks. (A)
GLP-1 was measured at fasting (6 hour) and 10 minutes after an oral fat load determined
by Mesoscale. Statistical difference between groups at fasting are indicated by different
uppercase letters, differences between groups 10 min post-gavage are indicated by
different lowercase letters and differences between the delta (10min-0hr) from baseline in
each group are indicated by different symbols by ANOVA with post-hoc Tukey test,
P<0.05.
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2.3.8

Treatment with GLP-2 receptor antagonist GLP-2 (3-33)

GLP-2 is known to increase intestinal fat absorption and chylomicron-triglyceride
secretion into plasma [9]. To determine if nobiletin increases intestinal triglyceride
secretion by increasing endogenous levels of gut-derived GLP-2, we treated chow, HFHC
and HFHC + nobiletin fed mice with 30 ng/day of the GLP-2 receptor antagonist GLP-2
(3-33) or PBS subcutaneously at 11am daily for 14 days following a 10-week feeding
period. Body weight did not significantly change between treatment groups during the 14
injection days (Figure 2-32B).

2.3.8.1

Effect of GLP-2 receptor antagonist, GLP-2 (3-33),
treatment on hepatic lipids

In similar experiments, another group found worsened hepatic steatosis following
treatment of high fat-fed mice with 30 ng and 60 ng GLP-2 (3-33) [29]. In the present
study, two hours after the dietary fat challenge, we found that GLP-2 (3-33) treatment did
not significantly increase hepatic triglyceride (Figure 2-33A) in HFHC-fed mice,
however, a significant increase was observed in GLP-2 (3-33)-treated HFHC + nobiletinfed mice compared to PBS control. GLP-2 (3-33) did not significantly increase hepatic
free cholesterol (Figure 33B) and hepatic cholesterol ester mass (Figure 2-33C) in either
HFHC or HFHC + nobiletin mice compared to vehicle controls.

2.3.8.2

Effect of GLP-2 receptor antagonist, GLP-2 (3-33),
treatment on physical gut parameters

GLP-2 is an intestinotrophic gut hormone and a treatment for short bowel syndrome [7].
Two hours after the dietary fat challenge, GLP-2 (3-33) treatment had no significant
effect on intestinal length (Figure 2-34A) in all three diet groups compared to vehicle
controls. Small intestinal weight and cecal weight were unchanged among all three diet
groups (Figure 2-34B&C).
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Figure 2-32 Treatment with a GLP-2 receptor antagonist, GLP-2 (3-33).
Male Ldlr-/- mice were fed a chow, HFHC, or HFHC + nobiletin diet for 10 weeks
(n=16/group). Mice were then treated at 11am daily for 14 days with 30 ng of GLP-2 (333) or PBS (control) by subcutaneous injection (n=8/treatment groups/diet). (A) Time
course of body weight during the 10-week feeding period. (B) Time course of body
weight during the 14 day injection period. Values are the mean ± SEM, * indicate
statistical difference between HFHC-fed and HFHC + nobiletin-fed mice by repeated
measures Two-Way Anova with post-hoc Tukey test, P<0.05. N.S. indicates no
statistical difference between control (PBS) and treatment (GLP-2 3-33) within a diet
group.
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Figure 2-33 Effect of treatment with a GLP-2 receptor antagonist, GLP-2 (3-33), on
hepatic lipids.
Male Ldlr-/- mice were fed a chow, HFHC, or HFHC + nobiletin diet for 10 weeks
(n=16/group). Mice were then treated at 11am daily for 14 days with 30 ng of GLP-2 (333) or PBS as a control by subcutaneous injections (n=8/treatment groups/diet). (A)
Hepatic triglycerides (B) Hepatic free cholesterol and (C) Hepatic cholesterol ester mass
2 hours after an olive oil gavage. Values are the mean ± SEM. Statistical difference
between control groups are indicated by different uppercase letters, differences between
treatment groups are indicated by different lowercase letters by ANOVA with post-hoc
Tukey test, P<0.05. Differences between control and treatment groups within a diet
group are indicated by * by Student's unpaired t-test P<0.05.
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Figure 2-34 Effect of treatment with a GLP-2 receptor antagonist, GLP-2 (3-33), on
physical gut parameters.
Male Ldlr-/- mice were fed a chow, HFHC, or HFHC + nobiletin diet for 10 weeks
(n=16/group). Mice were then treated at 11am daily for 14 days with 30 ng of GLP-2 (333) or PBS as a control by subcutaneous injections (n=8/treatment groups/diet). (A)
Small intestinal length, (B) Small intestinal weight and (C) Cecal weight 2 hours after an
olive oil gavage. Values are the mean ± SEM. Statistical difference between control
groups are indicated by different uppercase letters, differences between treatment groups
are indicated by different lowercase letters by ANOVA with post-hoc Tukey test,
P<0.05. Differences between control and treatment groups within a diet group are
indicated by * by Student's unpaired t-test P<0.05.

135

Small intestinal length
45

A
Length (cm)

A
40

A

a
B

35
30

a

b

PBS 3-33 PBS 3-33 PBS 3-33
Chow
HFHC HFHC +
Nob

Small intestinal weight
Tissue weight (g)

B
1.5

N.S.

1.0
0.5
0.0

C

PBS 3-33 PBS 3-33 PBS 3-33
Chow
HFHC HFHC +
Nob

Cecal weight

Tissue weight (g)

0.6
A

a

0.4
0.2
0.0

C
B

c

b

PBS 3-33 PBS 3-33 PBS 3-33
Chow
HFHC HFHC +
Nob

136

2.3.8.4

Effect of GLP-2 receptor antagonist, GLP-2 (3-33),
treatment on jejunal lipids following an olive-oil gavage

Pharmacological doses of GLP-2 have been shown to increase intestinal triglyceride
secretion [9]. To determine if nobiletin requires intact GLP-2 signaling to increase-TG
secretion from the intestine, we measured jejunal lipids two hours after an olive oil
gavage, as outlined in our experimental design (Figure 2-35A). GLP-2 (3-33) treatment
did not significantly change jejunal TG mass in chow, HFHC-fed or nobiletin treated
mice compared to vehicle controls (Figure 2-35B). Jejunal free cholesterol mass was not
significantly increased with GLP-2 (3-33) compared to vehicle controls (Figure 2-35C).

2.3.8.5

Effect of GLP-2 receptor antagonist, GLP-2 (3-33),
treatment on intestinal-TG secretion

The triglyceride content of plasma chylomicron and VLDL fractions were measured
before and at 2 hours following an olive oil gavage and poloxamer-407 administration in
mice treated with GLP-2 (3-33) for 14 days. GLP-2 (3-33) treatment did not significantly
alter triglyceride secretion in the chylomicron or VLDL fractions in chow HFHC-fed or
nobiletin-treated mice compared to vehicle controls (Figure 2-36A&B). GLP-2 (3-33)
treatment did not significantly alter apoB48 secretion at 2 hours in the chylomicron
fraction between diet groups (Figure 2-37).
Collectively, these results suggest that the GLP-2 (3-33) treatment did not significantly
impact postprandial hepatic, intestinal and plasma lipid metabolism. Moreover, the
assumed increase in endogenous levels of GLP-2 with nobiletin treatment appeared to not
be required for nobiletin's protection.
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Figure 2-35 Effect of treatment with a GLP-2 receptor antagonist, GLP-2 (3-33), on
jejunal triglycerides 2 hours after an olive oil gavage.
Male Ldlr-/- mice were fed a chow, HFHC, or HFHC + nobiletin diet for 10 weeks
(n=16/group). Mice were then treated at 11am daily for 14 days with 30 ng of GLP-2 (333) or PBS as a control by subcutaneous injections. Mice were fasted (6 hours) at the
beginning of the light cycle and injected with poloxamer-407 (i.p.) and 30 min later
received an olive oil via oral gavage (A). Jejuna were removed and cleaned for lipid
determinations. (B) Jejunal triglyceride mass and (C) Jejunal free cholesterol mass.
Values are the mean ± SEM. Statistical difference between control groups are indicated
by different uppercase letters, differences between treatment groups are indicated by
different lowercase letters by ANOVA with post-hoc Tukey test, P<0.05. Differences
between control and treatment groups within a diet group are indicated by * by Student's
unpaired t-test P<0.05.
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Figure 2-36 Effect of treatment with GLP-2 receptor antagonist, GLP-2 (3-33), on
intestinal TG secretion 2 hours after an olive oil gavage.
Male Ldlr-/- mice were fed a chow, HFHC, or HFHC + nobiletin diet for 10 weeks
(n=16/group). Mice were then treated at 11am daily for 14 days with 30 ng of GLP-2 (333) or PBS as a control by subcutaneous injections. Plasma was ultracentrifuged to
isolate the (A) chylomicron fraction and the (B) VLDL fraction. Triglyceride
concentrations were determined at baseline (6 hour fast) and at 2 hours after the olive oil
gavage. Values are the mean ± SEM. Statistical differences between control groups are
indicated by different uppercase letters at fasting (A-B) and 2 hours post-gavage (C-D)
by ANOVA with post-hoc Tukey test, P<0.05. Statistical differences between treatment
groups are indicated by different lowercase letters at fasting (a-c) and 2 hours postgavage (d-e) by ANOVA with post-hoc Tukey test, P<0.05. Different symbols indicate
statistical difference between the delta from baseline (2hr-0hr) in control groups (# or &)
and treatment groups (% or @) by ANOVA with post-hoc Tukey test, P<0.05.
Differences between control and treatment groups within a diet group are indicated by *
by Student's unpaired t-test P<0.05.
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Figure 2-37 Effect of treatment with a GLP-2 receptor antagonist, GLP-2 (3-33), on
intestinal apoB48 secretion 2 hours after an olive oil gavage.
Male Ldlr-/- mice were fed a chow, HFHC, or HFHC + nobiletin diet for 10 weeks
(n=16/group). Mice were then treated at 11am daily for 14 days with 30 ng of GLP-2 (333) or PBS (control) by subcutaneous injections. Plasma was ultracentrifuged to isolate
the chylomicron fraction. (A) Apob48 levels were measured by immunoblot and
normalized to albumin in the chylomicron fraction at baseline (6 hour fast) and at 2 hours
after the olive oil gavage. Representative immunoblot is shown below. Values are the
mean ± SEM. Statistical differences between control groups are indicated by different
uppercase letters at fasting (A-B) and 2 hours post-gavage (C-D) by ANOVA with posthoc Tukey test, P<0.05. Statistical differences between treatment groups are indicated by
different lowercase letters at fasting (a-c) and 2 hours post-gavage (d-e) by ANOVA with
post-hoc Tukey test, P<0.05. Different symbols indicate statistical difference between the
delta from baseline (2hr-0hr) in control groups (# or &) and treatment groups (% or @)
by ANOVA with post-hoc Tukey test, P<0.05. Differences between control and
treatment groups within a diet group are indicated by * by Student's unpaired t-test
P<0.05.
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2.3.9

Investigating the ability of nobiletin to correct metabolic
dysregulation and intestinal lipid metabolism in female Ldlr-/mice fed a HFHC diet

All nobiletin studies to date have been performed in male mice. To determine if
observations previously documented systemically as well as the intestine the intestine
extend to female mice, we examined the major outcomes of nobiletin treatment in one
study of female mice (n=59).

2.3.9.1

Nobiletin prevents HFHC-diet induced obesity in female
Ldlr-/- mice

Female Ldlr-/- mice were fed a chow, a HFHC diet, or a HFHC diet supplemented with
0.3% nobiletin (w/w) for 12 weeks. Weight rapidly increased in mice fed the HFHC diet,
which was prevented by supplementation of nobiletin to the same diet (Figure 2-38A).
The prevention of HFHC-induced weight gain was independent of caloric intake (Figure
38B). Moreover, gonadal and inguinal fat pad weights were significantly increased in
HFHC-fed mice and this increased adiposity was prevented with nobiletin treatment
(Figure 2-38C&D). Liver weight was also increased with HFHC-feeding, which was
prevented by nobiletin treatment (Figure 2-38E). Therefore as in male mice, nobiletin
prevents HFHC-diet induced weight gain and obesity.

2.3.9.2

Hepatic and plasma lipid metabolism in female Ldlr-/- mice

In female Ldlr-/- mice fed the HFHC diet, the presence of increased dietary fat and
cholesterol promoted the development of hepatic steatosis, as these mice displayed
elevated triglyceride, free cholesterol and cholesteryl ester mass in their livers (Fig 239A-C). Nobiletin-treatment significantly prevented hepatic triglyceride (Figure 2-39A)
but surprisingly, not cholesterol accumulation (Figure 2-39B&C). These effects on
hepatic lipids were reflected in plasma. HFHC-fed mice displayed a significant increase
in fasting plasma TG, which was corrected by nobiletin (Figure 2-40A). FPLC
fractionation revealed a 3-fold increase in the TG content of VLDL particles in HFHCfed mice (Figure 2-40B). Nobiletin treatment reduced the fasting VLDL-TG AUC by
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~50% (Figure 40B). As expected, HFHC-fed mice displayed a significant increase in
fasting plasma cholesterol (Figure 2-41A). The addition of nobiletin to the HFHC,
however, did not attenuate fasting plasma cholesterol levels (Figure 2-41B). FPLC
fractionation revealed a 5-fold increase in VLDL cholesterol and a 3-fold increase in
LDL cholesterol in HFHC-fed mice, whereas the addition of nobiletin had no effect on
these parameters (Figure 2-41B). Therefore, as in male mice, nobiletin prevents HFHC
diet-induced increases in fasting VLDL-TG in female Ldlr-/- mice. Unlike in male mice,
nobiletin does not prevent HFHC diet-induced perturbations in VLDL and LDL
cholesterol in female Ldlr-/- mice.
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Figure 2-38 Nobiletin prevents HFHC diet-induced weight gain and obesity in
female Ldlr-/- mice.
Female Ldlr-/- mice, (n=16-22/group) were fed a chow, a HFHC or a HFHC + nobiletin
diet for 12 weeks. (A) Body weight gain. (B) Caloric intake expressed as kcal/g body
weight/day. (C) Gonadal and (D) inguinal fat pad weights. (E) Liver weights of mice
sacrificed in the fasted state (n=7-8/group). Values are the mean ± SEM. * indicate
differences in body weight in HFHC-fed mice compared to HFHC + nobiletin-fed mice
by repeated measures Two-Way Anova with post-hoc Tukey test, P<0.05. Different
letters are statistically different, by ANOVA with post-hoc Tukey test, P<0.05.
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Figure 2-39 Nobiletin attenuates hepatic lipid accumulation in HFHC-fed female
Ldlr-/- mice.
Female Ldlr-/- mice, (n=16-22/group) were fed a chow, a HFHC or a HFHC + nobiletin
diet for 12 weeks. Mice were sacrificed after a 6 hour fast. Hepatic (A) triglyceride (TG)
(B) free cholesterol (FC) and (C) cholesteryl ester (CE) mass determined following lipid
extraction. Values are the mean ± SEM, different letters are statistically different, by
ANOVA with post-hoc Tukey test, P<0.05.
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Figure 2-40 Plasma triglyceride analyses in nobiletin treated female Ldlr-/- mice.
Female Ldlr-/- mice, (n=16-22/group) were fed a chow, a HFHC or a HFHC + nobiletin
diet for 12 weeks. Mice were sacrificed after a 6 hour fast. (A) Fasting plasma total
triglyceride (TG). Plasma was subjected to fast protein liquid chromatography (FPLC)
and TG concentrations were measured in eluted fractions (n=7-8/group). (B) Fasting
plasma triglyceride (TG). (C) Plasma FPLC VLDL triglyceride (TG) area under the curve
(AUC) (fractions 5-10). Values are the mean ± SEM, different letters are statistically
different, by ANOVA with post-hoc Tukey test, P<0.05.
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Figure 2-41 Plasma cholesterol analyses in nobiletin treated female Ldlr-/- mice.
Female Ldlr-/- mice, (n=16-22/group) were fed a chow, a HFHC or a HFHC + nobiletin
diet for 12 weeks. (A) Fasting plasma total cholesterol. Plasma was subjected to fast
protein liquid chromatography (FPLC) and cholesterol concentrations were measured in
eluted fractions (n=7-8/group). (B) Fasting plasma cholesterol. (C) Plasma FPLC VLDL
cholesterol area under the curve (AUC) (fractions 5-10). (D) Plasma FPLC LDL
cholesterol AUC (fractions 11-19). Values are the mean ± SEM, different letters are
statistically different, by ANOVA with post-hoc Tukey test, P<0.05.
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2.3.9.3

Nobiletin attenuates HFHC-diet induced jejunal lipid
accumulation in female Ldlr-/- mice

Lipid mass was quantified in jejunal mucosal scrapings of 6 hour-fasted mice. The HFHC
diet-induced increase in jejunal triglyceride mass was markedly attenuated by the
addition of nobiletin to the same diet (Figure 2-42A). Cholesteryl ester mass was also
increased in the jejunum of HFHC fed mice, however, a similar increase was detected
with nobiletin treatment (Figure 2-42B). Therefore, as in male mice, nobiletin prevents
HFHC diet-induced increases in fasting jejunal TG accumulation in female Ldlr-/- mice.
Unlike in male mice, nobiletin does not prevent HFHC-diet induced jejunal CE
accumulation.

2.3.9.4

Postprandial jejunal lipid metabolism in female Ldlr-/- mice

To determine if nobiletin prevents intestinal triglyceride accumulation in the postprandial
state in female mice, we quantified lipid mass in jejunal mucosa scrapings, 2-hours after
an olive oil gavage (Figure 2-43A). Triglyceride mass in the mucosa of the jejunum did
not differ between diet groups, rather a trend for increase in mass was observed in the
nobiletin treated mice (Figure 2-43A). Total cholesterol mass did not differ between diet
groups (Figure 2-43B). Therefore unlike in male mice, nobiletin does not prevent HFHC
diet-induced increases in post-olive oil gavage jejunal TG accumulation in female Ldlr-/mice.
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Figure 2-42 Nobiletin attenuates fasting jejunal lipid accumulation in HFHC-fed
female Ldlr-/- mice.
Female Ldlr-/- mice, (n=16-22/group) were fed a chow, a HFHC or a HFHC + nobiletin
diet for 12 weeks. Mice were sacrificed after a 6 hour fast and jejunum was removed for
lipid analysis (n=7-8/group). Fasting (A) triglyceride (TG) and (B) cholesteryl ester (CE)
mass in jejunal mucosa scrapings. Values are the mean ± SEM, different letters are
statistically different, by ANOVA with post-hoc Tukey test, P<0.05.
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Figure 2-43 Postprandial jejunal lipid accumulation in HFHC-fed female Ldlr-/mice.
Female Ldlr-/- mice, (n=16-22/group) were fed a chow, a HFHC or a HFHC + nobiletin
diet for 12 weeks. Mice were fasted (6 hours), injected with poloxamer-407 (i.p.) and 30
min later received an olive oil gavage (A). Jejuna were removed and cleaned for lipid
determinations (n=8-12/group). Jejunal mucosa (B) triglyceride (TG) and (C) total
cholesterol (TC) mass. Values are the mean ± SEM, different letters are statistically
different, by ANOVA with post-hoc Tukey test, P<0.05. N.S. indicates no statistical
significance.
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2.3.9.5

Nobiletin enhances intestinally derived TG secretion
following an oral fat load in female Ldlr-/- mice

To determine if nobiletin prevents the HFHC diet-induced delay in intestinal TG
secretion in female mice as it does in male mice, we measured plasma, chylomicron
fraction and VLDL fraction triglycerides before and 2 hours following an olive oil
gavage in mice treated with poloxamer-407. HFHC-fed mice displayed significantly
lower plasma triglyceride secretion 2 hours after the olive oil gavage and no difference
was observed with nobiletin treatment (Figure 2-44A). HFHC-fed mice also displayed
delayed secretion of both chylomicron TG and VLDL TG (Figure 2-44B&C). Nobiletin
significantly increased TG secretion in both fractions compared to HFHC alone (Figure
2-44B&C). ApoB48 secretion at 2 hours in the chylomicron fraction was not different
among the 3 diet groups. However, absolute values at fasting and 2-hours post gavage
were similar in HFHC and HFHC + nobiletin-fed mice (Figure 2-44D) suggesting that
nobiletin increased the amount of TG per chylomicron particle secreted. Therefore
nobiletin increases intestinal TG secretion in both male and female Ldlr-/- mice compared
to mice fed the HFHC diet alone.

2.3.9.6

Expression of genes involved in intestinal lipid metabolism
in female Ldlr-/- mice

While it appeared that nobiletin increased intestinal triglyceride secretion 2 hours after an
acute dietary fat challenge, nobiletin did not prevent HFHC-diet-induced increases in
jejunal lipid accumulation following the olive oil gavage. Therefore, the remaining
triglyceride mass may be derived from de novo synthesis. Srebf1c expression in HFHCfed mice was significantly increased 2 hours post-olive oil gavage, which was not
corrected with nobiletin treatment (Figure 2-45A). There was a non-significant trend for
increase in Plin2 expression with nobiletin treatment compared to HFHC-fed mice.
Therefore, unlike in male mice, nobiletin did not prevent HFHC-diet induced increase in
Srebpf1c expression in female Ldlr-/- mice. Nobiletin treatment appears to induce a trend
for increase in Plin2 expression in both male and female Ldlr-/- mice.
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Figure 2-44 Nobiletin enhances intestinal TG secretion following an oral fat load in
female Ldlr-/Female Ldlr-/- mice, (n=16-22/group) were fed a chow, a HFHC or a HFHC + nobiletin
diet for 12 weeks. Mice were fasted (6 hours) injected with poloxamer-407 (i.p.) and 30
min later received an olive oil gavage (n=8-12/group). (A) Plasma triglyceride (TG)
concentration at baseline (6 hour fast) and at 2 hours after an olive oil gavage. Plasma
was ultracentrifuged to isolate the (B) chylomicron fraction and the (C) VLDL fraction
and TG concentrations are shown at baseline (6 hour fast) and at 2 hours after the olive
oil gavage. ApoB48 levels were measured by immunoblot and normalized to albumin in
the (D) chylomicron fraction. Values are the mean ± SEM. Statistical difference between
groups at fasting are indicated by different uppercase letters, differences between groups
2 hours post-gavage are indicated by different lowercase letters and differences between
the delta (2hr-0hr) from baseline in each group are indicated by different symbols by
ANOVA with post-hoc Tukey test, P<0.05.
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Figure 2-45 Expression of genes involved in intestinal lipid metabolism.
Female Ldlr-/- mice, (n=16-22/group) were fed a chow, a HFHC or a HFHC + nobiletin
diet for 12 weeks. Mice were fasted (6 hours), injected with poloxamer-407 (i.p.) and 30
min later received an olive oil gavage (n=8-12/group). Expression of (A) Srebf1c and (B)
Plin2 in jejunal mucosa scrapings by qRT-PCR. Values are the mean ± SEM, different
letters are statistically different, by ANOVA with post-hoc Tukey test, P<0.05.
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2.3.9.7

Nobiletin prevents HFHC-diet-induced physical changes to
gut parameters in female Ldlr-/- mice.

The HFHC-diet significantly reduced small intestinal length (Figure 2-46A) and weight
in female mice (Figure 2-46B). Nobiletin significantly attenuated HFHC-diet induced
shortening of the small intestine and increased intestinal weight to values observed in
chow-fed mice (Figure 2-46A&B). The HFHC-diet significantly reduced cecal mass,
independent of nobiletin treatment (Figure 2-46C). The prevention of HFHC diet-induced
shortening of the small intestine by nobiletin in female Ldlr-/- mice, as shown in male
mice, suggests an increase in endogenous GLP-2 action.
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Figure 2-46 Nobiletin prevents HFHC-diet induced physical changes to gut
parameters in HFHC-fed female Ldlr-/- mice.
Female Ldlr-/- mice, (n=16-22/group) were fed a chow, a HFHC or a HFHC + nobiletin
diet for 12 weeks. (A) Small intestinal length, (B) small intestinal weight and (C) cecal
weight 2 hours post-olive oil gavage. Values are the mean ± SEM, different letters are
statistically different, by ANOVA with post-hoc Tukey test, P<0.05.
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Discussion

3

Summary

There is intense debate whether alteration in intestinal lipid metabolism is the result of a
normal adaptation to ensure absorption of chronic high-fat feeding or the result of
obesity-induced dysregulation in mice [9]. In this thesis, we showed that 10 weeks of
HFHC-feeding caused aberrant intestinal insulin signaling and increased intestinal de
novo lipogenesis, which provided increased substrate for chylomicron synthesis, CLD
formation and therefore prolonged postprandial lipemia. Furthermore, the increased free
fatty acid concentrations in the insulin resistant HFHC-fed mice were linked to increased
intestinal triglyceride synthesis providing even more TG substrate. The addition of
nobiletin to the HFHC diet improved intestinal insulin sensitivity and prevented intestinal
lipid accumulation from de novo pathways, thereby allowing for efficient dietary
triglyceride excursion from the intestine into plasma. In addition to enhanced intestinal
TG excursion, we observed a shortened period of postprandial lipemia with nobiletin
treatment compared to mice fed the HFHC diet alone, which could play a role in
nobiletin's anti-atherogenic protection.
All of the studies highlighted in Chapter 2 are acute dietary fat challenges following a 6
hour fast. Therefore, we were not testing an acute molecular function of nobiletin. Rather,
our acute dietary challenges, containing no nobiletin, were testing the influence of the
background diet on handling of lipid by the intestine. As such, I became very interested
in further exploring the dysregulation of nutrient signaling involved with HFHC feeding
and the potential protection by nobiletin. We showed that HFHC feeding caused
increased GIP stimulation and increased β-cell mass, which contributed to fasting and
glucose-stimulated hyperinsulinemia. The addition of nobiletin to the HFHC diet
corrected the GIP response to the ingestion of glucose and maintained normal β-cell
mass, thereby allowing for normal insulin secretion and enhanced glucose tolerance. A
potential mechanism involving gut hormones was evidenced by the increase in fasting
and post-olive oil gavage of GLP-1, and presumably GLP-2, with nobiletin treatment.
The involvement of GLP-2 in nobiletin's mechanism of action is not only in agreement
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with the aforementioned increased intestinal TG secretion we observed with nobiletin
treatment, but also with the prevention of HFHC-diet induced shortening of the small
intestine in nobiletin supplemented mice. I investigated the influence of GLP-2 signaling
on intestinal lipid metabolism using the GLP-2 receptor antagonist, GLP-2 (3-33). I
expected that the nobiletin-treated mice would be the most vulnerable to the antagonist
treatment resulting in inhibition of the nobiletin-induced improvements in intestinal lipid
metabolism. To our surprise, the antagonist did not impact intestinal TG secretion rates in
chow-fed or HFHC-fed mice. In HFHC+nobiletin-fed mice, we observed a trend for
reduced intestinal TG excursion with GLP-2 (3-33) treatment, suggesting that GLP-2
signaling may play a small role in nobiletin's ability to increase intestinal TG secretion. If
anything, these studies underscore the gaps in our knowledge of the involvement of gut
hormones in postprandial lipemia.
Finally, I investigated the protection of nobiletin in HFHC-fed female Ldlr-/- mice. As in
male Ldlr-/- mice, nobiletin prevented HFHC-diet induced obesity, decreased VLDL
triglycerides, attenuated small intestinal shortening and reduced hepatic and jejunal
triglyceride accumulation. Conversely, nobiletin did not attenuate HFHC diet-induced
increases in LDL cholesterol and hepatic cholesterol accumulation in female Ldlr-/- mice,
all of which are corrected by nobiletin in male Ldlr-/- mice. This study provides evidence
for either sex-specific responses to nobiletin treatment, narrowing of the molecular
targets of nobiletin, and/or highlights sex-differences in metabolic dysregulation.
Ultimately, this study highlights the importance of studying both sexes in a prevention
model of metabolic syndrome.

3.1 Nobiletin prevents HFHC diet-induced fasting jejunal
lipid accumulation
Previously, our laboratory has shown that significant levels of triglyceride (TG) mass
remained in the liver and in the intestine of high fat-fed mice following a 6 hour fast but
not in mice fed the same high fat diet supplemented with nobiletin [1]. The reduction in
hepatic TG accumulation was due to increased expression of Pgc1α and Cpt1α as well as
an increased hepatic fatty acid oxidation capacity [1]. Furthermore, correction of the
hyperinsulinemia by nobiletin resulted in attenuation of Srebp-1c-mediated de novo fatty
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acid synthesis. While the reduced intestinal TG accumulation was not investigated, this
study importantly demonstrated that caloric intake, intestinal TG absorption, and lean
body mass was not different between HFHC-fed and HFHC + nobiletin treated mice [1].
This information, along with the unchanged jejunal fatty acid oxidation capacity between
nobiletin-treated mice compared to mice fed the HFHC-diet alone observed in the present
studies, prompted us to investigate the contributions of de novo lipid synthesis and
dietary fat handling to jejunal lipid accumulation.

3.2

Intestinal insulin signaling

The increased and unregulated adipocyte lipolysis associated with insulin resistance has
been a well-documented source of and contributor to FA substrates for TG synthesis and
VLDL production. In our fasting-refeeding experiments, where mice were re-fed their
respective diets for 2 hours, we observed a significant increase in plasma insulin and FFA
in HFHC-fed mice, which was normalized by nobiletin. While this experiment was a
more physiological representation of nutrient-stimulated insulin secretion and resulting
suppression of adipocyte lipolysis, the protective effects of nobiletin were likely due to a
chronic prevention of peripheral insulin resistance rather than an acute effect of nobiletin
on adipocytes with re-feeding HFHC + nobiletin. We observed no difference in jejunal
Akt phosphorylation between diet groups. However, we showed that mTORC1 remains
sensitive to insulin signaling in the fasted and re-fed state in HFHC-fed mice. FoxO1
phosphorylation, however, was significantly blunted particularly in the re-fed state in
HFHC-fed mice. These are the first studies to establish that HFHC-feeding induced a
bifurcation in intestinal insulin signaling, a concept previously reported to occur in the
liver. Importantly, nobiletin treatment significantly increased in FoxO1 phosphorylation
in the re-fed state, which may contribute to the decreased postprandial lipemia observed
in these mice compared to HFHC-fed mice. While the contribution of intestinal
gluconeogenesis to hyperglycemia in HFHC-fed mice was not directly investigated in our
studies, it has been previously reported in rats that intestinal gluconeogenesis
significantly contributes to endogenous glucose production [2]. Interestingly, increased
expression of glucose 6 phosphate, a direct target of FoxO1, is significantly upregulated
in the small intestine of diabetic rats [3]. Therefore the ability of nobiletin to increase

172

postprandial FoxO1 phosphorylation may make an important contribution to the
increased tolerance observed in our oral glucose tolerance tests.
While mTORC1 phosphorylation was not significantly different between diet groups, the
expression of its downstream effector, Srebf1-c, was significantly increased in both the
fasted and re-fed states of HFHC-fed mice. Nobiletin treatment completely corrected
fasting Srebf1-c expression and significantly attenuated its increased expression in the refed state in male Ldlr-/- mice. The impact of this intestinal dysregulation of insulin
signaling was confirmed ex vivo where the capacity to synthesize jejunal fatty acid and
triglyceride was significantly elevated in HFHC-fed mice, but not nobiletin-treated mice.
Therefore the prevention of HFHC-diet induced selective insulin resistance exerted by
nobiletin treatment played an important role in limiting excess TG substrate for intestinal
lipid storage (Summary Figure 3-1).
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Figure 3-1 Triglyceride processing in enterocytes in an insulin sensitive and insulin
resistant state.
Under normal conditions of dietary fat absorption, insulin stimulates mTORC1 and
FoxO1 phosphorylation, leading to increased SREBP-1c-mediated de novo lipogenesis
(DNL) and decreased gluconeogenesis, respectively. During insulin resistance, the
increased insulin-stimulated DNL and enhanced circulating free fatty acids (FFA)
provide excess substrate for TG storage in CLDs pool and chylomicron particle
formation, contributing to the overproduction of chylomicron particles.
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3.3

Postprandial intestinal lipid metabolism

Several studies highlight that during lipid absorption, CLDs are formed as temporary
storage sites for dietary TG. Upon a secondary dietary fat stimulus, CLDs can undergo
remodeling for lipolysis and transport to the ER for chylomicron production [4, 5].
Glucose ingestion has also been shown to stimulate chylomicron production in humans
[6]. The increased fasting TG storage from de novo and dietary sources in HFHC-fed
mice and the significantly diminished TG storage in nobiletin-treated mice led us to
investigate postprandial intestinal-TG secretion rates in these mice. First, electron
micrographs demonstrated a substantial increase in number and size of CLDs in a HFHCfed mouse compared to fasting, which were considerably diminished with nobiletin
treatment. Our assumption that the phenotypes observed by TEM in one mouse per diet
group would be representative across the diet groups was supported by the biochemical
quantifications performed in all of the mice. Since the olive oil gavage contained a
radiolabeled tracer, we were able to compare dietary TG to the total TG mass within the
small intestine 2 hours post-gavage. We did not observe a significant difference in
radiolabeled lipids throughout the entire small intestine between diet groups 2 hours postgavage, suggesting that the same amount of dietary TG is temporarily stored in the
intestines of mice in all three diet groups. When comparing total TG mass in the small
intestine 2-hours post-gavage, the HFHC-fed mice still had a higher AUC, particularly in
the jejunum. This suggests that the elevated TG mass in HFHC-fed mice following a 6
hour fast was not depleted even 2 hours following dietary fat stimulation. Furthermore,
jejunal Srebf1-c expression was significantly elevated 2 hours post-olive oil gavage in
HFHC-fed mice. Therefore, the significant increase in post-olive oil gavage intestinal
lipid accumulation in HFHC-fed mice was contributed to by both fasting and postprandial
de novo lipogenesis by means of mTORC1 hypersensitivity to insulin signaling. By
contrast, the correction of intestinal insulin sensitivity by nobiletin normalized fasting
intestinal TG mass and the decreased post-olive oil Srebf1-c expression, together limiting
the post-olive oil gavage intestinal lipid accumulation.
The poloxamer-407 studies revealed that the ability of nobiletin treatment to limit
intestinal lipid storage was also achieved through significant increases in secretions of
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total TG mass (from stored and dietary pools) and in radiolabeled TG (dietary only) into
plasma compared to HFHC-fed mice. The increases in intestinal TG secretion with
nobiletin treatment were consistent in the chylomicron and VLDL fractions of plasma.
We assumed that the VLDL fraction was predominantly intestinally derived, by virtue of
the rapid rise in plasma VLDL-TG following the acute oral fat challenge. Measuring
radiolabeled VLDL-TG following an oral gavage of olive oil containing 3H-triolein or
treating mice with orotic acid, which directly inhibits hepatic VLDL secretion [7], may
provide increased certainty for this concept. However, previous tyloxapol studies (same
effect as poloxamer-407) reported by our lab demonstrated that the addition of nobiletin
to a high-fat diet decreased fasting VLDL-TG secretion to less than 1 mmol/L/h [1]; this
represents less than 20% of the TG secretion rate into the plasma VLDL-TG fraction
observed in the present study in HFHC + nobiletin-treated mice post-olive oil gavage. In
high fat-fed mice, the fasting VLDL-TG secretion rate was decreased by nobiletin [1],
whereas in the present study nobiletin increased the VLDL-TG secretion rate post-oil
gavage, thus providing further evidence for an intestinal-specific effect of nobiletin on
intestinal-TG secretion.
Our non-poloxamer-407 studies, by contrast, demonstrated the potential detrimental
effects of the increased jejunal TG accumulation in HFHC-fed mice. Increased jejunal
TG accumulation lead to increased substrate for lipoprotein formation, which
significantly contributed to HFHC-diet induced hypertriglyceridemia. I demonstrated
through an estimation of poloxamer-407 to non-poloxamer-407 changes in chylomicronTG secretion that nobiletin significantly increased the plasma clearance and presumably
peripheral uptake of intestinally-derived TG. While our studies did not directly measure
LPL activity, VLDL and chylomicron particles compete for LPL-mediated hydrolysis,
where the latter is the preferred substrate [8]. Therefore prolonged chylomicron secretion
exhibited by HFHC-fed mice concomitantly extends the retention of hepatic and/or
intestinal VLDL particles in the circulation. Conversely, the efficient secretion and
clearance of chylomicrons in nobiletin-treated mice would appear more favourable.
Reduced intestinal TG secretion following an olive oil gavage has been repeatedly shown
in high fat diet-induced obese mice compared to lean mice as reported in this thesis and
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by others [9] suggesting that differences in energy status may be driving alterations in
intestinal triglyceride secretion. As such, HFHC-fed mice are in a less energy demanding
state than the lean, nobiletin-treated mice following a 6 hour fast. This is further
supported by the increased energy expenditure by nobiletin, observed in both prevention
and intervention model of HFHC-diet induced obesity [10]. Measuring intestinal TG
secretion rates at early, middle and late phases of obesity-reversal with nobiletin
treatment may allow for the delineation of the requirement of obesity for delayed
intestinal TG secretion. Additionally, our lab has recently shown that the addition of
naringenin, a grapefruit-derived flavonoid, to a chow diet increased energy expenditure
compared to pair-fed littermates fed the chow diet alone [11]. Determining the ability of
nobiletin to increase intestinal TG secretion independent of obesity may uncover direct
molecular targets.

3.4
Nobiletin as a potential stimulus of gut hormone
secretion
The measurement of gut hormones and their inhibitor, DPP4, led us to uncover some
interesting findings. We showed that HFHC-fed mice have increased fasting DPP4
activity, increased fasting and post-OGTT GIP levels and unchanged fasting and postOGTT GLP-1 levels. Nobiletin-treated mice also had increased fasting DPP4 activity,
despite this, fasting plasma GLP-1 was significantly elevated. Furthermore, increased
plasma GIP levels were significantly attenuated with nobiletin treatment. DPP4 activity
has been previously reported to be elevated in diabetic humans and mice; its inhibition is
thus favourable in the setting of diabetes to promote insulin secretion [12, 13]. Our
HFHC-fed mice, however, were not diabetic, as evidenced by the increased β-cell mass.
Rather, our HFHC-fed mice, but not HFHC + nobiletin-fed mice, were hyperinsulinemic
in the fasting and postprandial state, independent of increased DPP4 activity. In addition
to its insulinotropic role, GIP signaling promotes TG storage in adipocytes in response to
fat ingestion [14]. In the setting of high fat-feeding, hyper-secretion of GIP in turn
potentiates obesity and hyperinsulinemia [14]. Interestingly, mice that lack the GIP
receptor are protected from high fat diet-induced obesity due to enhanced energy
utilization rather than storage of TG [14]. Therefore the prevention of GIP hyper-
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secretion with nobiletin treatment may play an important role in nobiletin's ability to
prevent obesity and hyperinsulinemia in HFHC-fed mice. Furthermore, the prevention of
GIP hyper-secretion with nobiletin treatment provided mechanistic insight into nobiletin
ability to increase energy expenditure. Potential experiments to test this include treating
HFHC + nobiletin-fed mice with GIPR agonists or inactive GIP analogues. Studies in
humans and in rodents have shown that the half-life of GIP is slightly longer than that of
GLP-1, suggesting that DPP4 preferentially targets GLP-1 [15]. Therefore, the increased
GLP-1 levels, but not GIP levels, observed in nobiletin-treated mice may indicate a
change in DPP4-substrate interaction.
This was the first study, to our knowledge, to measure intestinal TG secretion in mice
treated with GLP-2 (3-33). Despite increased plasma GLP-1, and presumably GLP-2, in
the fasted and post-olive oil gavage states of nobiletin treated mice, GLP-2 receptor
antagonist treatment did not impact intestinal TG secretion or metabolic protection.
Previously, GLP-2 (3-33) has been shown to exacerbate hepatic lipid accumulation in
high fat-fed mice, but not chow-fed mice. Furthermore, GLP-2 (3-33) was shown to
decrease small intestinal weight, crypt-villus height and increase villus apoptosis in both
lean and high-fat fed mice [16, 17]. In this study, we showed that HFHC-fed mice and
HFHC+nobiletin-fed mice have increased hepatic TG and CE levels, thus confirming
GLP-2 (3-33) action. Since all of the mice in our study were administered an olive-oil
gavage, accurate crypt-villus measurements could not be made with a high level of
certainty. This was a clear limitation in our study for confirming GLP-2 (3-33) action. An
alternative experimental design would be to acutely treat mice with liraglutide, a GLP-1R
agonist, and measure intestinal TG secretion following an olive-oil gavage. Liraglutide
treatment should significantly decrease intestinal TG secretion as shown previously [18]
and we would be able to determine if the assumed increased endogenous levels of GLP-2
in nobiletin-treated mice can counteract this effect.
The prevention of HFHC-diet induced shortening of the small intestine with nobiletin
treatment suggested a possible involvement of intestinotrophic peptide, GLP-2. A recent
study has shown that when mice are fed a low-fat diet with reduced fibre content, a
shortening of the small intestine and shrinkage of the ceca of these mice were to the same
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extent as observed in high-fat fed mice [19]. Therefore, the reduced fibre content of highfat diets, and not obesity, plays a major role in this phenotype. Specifically, the authors
highlight that the reduced cecal short chain fatty acids limits energy substrates for
intestinal growth [19]. Since the nobiletin-treated mice ingest the same amount of fibre as
the HFHC-fed mice, yet prevent a shortening of the small intestine, it is possible that
nobiletin plays a role in modulating short chain fatty acid production in the gut.
Interestingly, diets high in fibre or short chain fatty acids have been shown to increase
intestinal proglucagon mRNA levels [15], the precursor of both GLP-1 and GLP-2.
Specifically, butyrate has been shown to increase plasma GLP-2 concentrations in rats
[20]. Therefore, nobiletin may increase gut hormone secretion through a short chain fatty
acid-dependent mechanism. First, it would be important to measure short chain fatty acid
concentrations in nobiletin-treated mice. This could be further investigated by feeding the
HFHC + nobiletin-diet to mice treated with antibiotics or to germ-free mice, which would
inhibit or prevent short chain fatty acid formation, and measure circulating gut hormones.

3.5
Investigating the ability of nobiletin to correct
metabolic dysregulation and intestinal lipid metabolism
in female Ldlr-/- mice fed a HFHC diet
When comparing the major outcomes of nobiletin treatment in previously documented
studies in male Ldlr-/- mice to the current female mice study, the protection against
obesity and perturbed TG metabolism but not cholesterol metabolism was achieved. In
terms of intestinal lipid metabolism, nobiletin attenuated fasting TG accumulation, which
would suggest a decrease in de novo lipogenesis. Following an olive oil gavage, nobiletin
treatment did increase chylomicron-TG secretion, however, a considerable amount of TG
remained in the jejunum. Correspondingly, Srebf-1c expression was significantly
elevated in both HFHC and HFHC + nobiletin-fed mice, suggesting that nobiletin did not
fully correct intestinal insulin resistance in females. It was also surprising to see a
protection from obesity, but not of perturbed plasma and hepatic cholesterol metabolism.
However, our lab has previously reported in male mice that 0.1% nobiletin reduced
plasma cholesterol concentrations to the same extent as 0.3% nobiletin treatment, without
preventing obesity [1]. Therefore in male Ldlr-/- mice, mechanism for nobiletin's lipid-
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lowering effects are independent of obesity prevention. Additionally, it has been
previously shown that high-fat (no cholesterol) feeding and high-fat (1.25% cholesterol)
significantly increases hepatic cholesterol accumulation in C57BL/6J female compared to
male mice [21]. This may suggest a role of estrogen in the potentiation of
hypercholesterolemia in the absence of obesity, an effect resistant to nobiletin treatment.
Further studies are required to test this concept. Furthermore, in view of the failure of
nobiletin to correct abnormal cholesterol metabolism in female mice, future studies in
female Ldlr-/- mice should investigate other parameters of nobiletin's metabolic
protection, particularly the prevention of atherosclerosis.

3.6

Final conclusions

Nobiletin prevents high fat-diet induced metabolic dysregulations through actions in a
variety of tissues in addition to its clock amplitude enhancing properties [53] (Figure 32). In this thesis, the mechanisms underlying the prevention of intestinal triglyceride
retention by nobiletin were investigated. In male Ldlr-/- mice, nobiletin 1) decreased
fasting intestinal TG storage by correcting intestinal insulin signaling, which resulted in
normalization of de novo lipogenesis; 2) attenuated intestinal TG accumulation and
postprandial lipemia in response to an oral fat load by increasing chylomicron-TG
secretion into plasma and enhancing plasma triglyceride clearance. The mechanisms
underlying the increased chylomicron-TG secretion were investigated using a GLP-2R
antagonist; however, antagonist administration did not inhibit nobiletin-induced
chylomicron secretion. The mechanisms underlying the prevention of hyperinsulinemia
by nobiletin were also investigated. In male Ldlr-/- mice, nobiletin: 1) normalized fasting
and post-glucose gavage levels of the incretin GIP and 2) prevented pancreatic β-cell
mass overexpansion. Finally, the metabolic protection by nobiletin was investigated, for
the first time, in HFHC-fed female mice. In female Ldlr-/- mice, nobiletin: 1) prevented
HFHC-diet induced weight gain; 2) decreased fasting intestinal TG storage; 3) increased
chylomicron-TG secretion in response to an oral fat load and 4) attenuated hepatic TG
mass. Unlike the male Ldlr-/- mice, nobiletin did not prevent perturbed cholesterol
metabolism. Collectively, these studies provide evidence for the intestinal contribution to
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dyslipidemia, the therapeutic utility of nobiletin and the importance of investigating both
sexes.
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Figure 3-2 Summary of previously known and current effects of nobiletin in a
mouse model of the metabolic syndrome.
In Ldlr-/- mice, previous studies investigated nobiletin’s mechanism of action with a
primary focus on the liver (left). Nobiletin reduces apoB100 secretion by reducing
SREBP-1c-mediated lipogenesis and increasing fatty acid oxidation. Correspondingly,
nobiletin attenuates plasma TG and cholesterol levels. Nobiletin prevents adiposity,
improves insulin sensitivity and increases glucose uptake in muscle. Whole-body energy
expenditure is enhanced by nobiletin. In this thesis, the protection by nobiletin in the
intestine as well as other tissues was investigated in male (right in bold) and female mice
(pink bold). Novel findings from studies in this thesis are indicated in bold. Nobiletin
decreased fasting jejunal lipid accumulation by correcting intestinal insulin signaling and
thereby normalizing de novo lipogenesis (DNL). Nobiletin increased chylomicron-TG
(CM-TG) secretion into plasma in response to an oral fat load, a mechanism independent
of GLP-2. Following an oral fat load, nobiletin increased CM-TG clearance. Nobiletin
prevented fasting and post-glucose load hyperinsulinemia through a correction of incretin
GIP secretion and a prevention of β-cell mass expansion. The metabolic protection by
nobiletin was investigated in female Ldlr-/- (pink). Nobiletin prevented obesity and
normalized plasma and hepatic TG levels. However, nobiletin did not correct plasma and
hepatic cholesterol levels, which may limit nobiletin’s athero-protection.
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